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ABSTRACT
The major hurdle in transderma' drug delivery is the barrier property of stratum
corneum. This barrier can be overcome by using electroporation. Eh!droporation
involves the application of exponentially decaying high vottage pulses of short
duration, which results in a transient increase in skin's permeability. This application
of electroporation in transdermal drug delivery is at its earty stages of development
and needs to be studied in detail.
Objeetiv..:
1) To optimize the electroporative transdermal drug delivery by investigating the
following:
i) relationship between U...- (voltage drop applied across th4:t pulse delivery
electrodes) and U_ (voltage drop across skin).
Ii) effect of electrode design on U_.
iii) inftuence of U_, pulse iength ('t), and number of pulses on the transdennal
delivery of a model ftourescent molecule, i.e., terazosin hydrochloride (TRZ).
2) To investigate safety issues related to eJectroporative delivery by studying the
fo'lowing:
i) reversibility of skin's enhanced penneability
ii) histological changes in the skin due to electroporation
In-vitro experiments were performed using freshly excised skin from hair1ess
rats, assembled in aaJStom.designed cells. Gene Pu"'l1 (Bic Rad, CA, USA) fitted
with custom designed AglAgCI electrodes was used for generating exponentially
decaying electroporation pulses. Tektron~- 5111 storage oscilloscope (Oregon,
USA) was used for measuring the vcMtage drop across the skin {U....J and the current
ftowing across the skin. TRZ was detected using HPLC with fluorescent detector.
R..uttl: Use of eIectroporation significantly increased the transdermal delivery of
TRL For example, electroporative delivery with 20 pulses of U_ = 500 V, t =
20ms resulted in 15 times increased transdermal delivery of TRZ. as compared to
passive diffusion. A U_ of 300 V (corresponding U_ 66 V) seemed to be the
minimum voftage required to make a significantenhancementeompared to the control.
The delivery of TRZ increased with an increase in U_, pulse length and number
of pulses. However, In order to maintain skin safety while achieving a reasonable
increase in the permeability of skin the upper limit forU~ anc1 pulse length seem
to be SOOV (U_ 88 V)and 20 ms, respectively. At U_ of 600 V and at pulse
length 60 ms the damage to the skin seems to be v8fY apparent. The U_ values
were about 1/2 to 1/5 thatofU_depending onthe vortage used. 8ectrode design
and area also had profoUnd etrects on transdermal drug delivery. The pH,
macroscoptc, and mtcroscopic changes associated with the skin after pulsing indicate
that the use ofa large electrode would rrunimize the: damage to the skin in comparison
to a small electrode.
Conclusion.: EJectroporative transdermal delivery of TRZ was markedly influenced
by U......, pulse length, number of pulses and electrode design. These factOfS can
be controlled to make this technique efficient and safe.
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l. Introduction
1.0 Drug delivery systems
The prtncipal obfectjve of any drug delivery system is to promptfy attain a
predictable therapeutic quantity of drug at a proper site in the body and maintain a
desired concentration. The optimized drug delivery system is intended to produce
maximum simultaneous safety, effectiveness, and reliability. Additionally. it should be
poss;be to manufacture the drug delivery system on a large scale with reproducible
product quality (YOf'k 1992). Reproduci~ product quality requires physical and
chemical stability, any necessary preservation against microbial contamination,
unifonn dosage, acceptability to users which includes both the patients and the
prescribers, suitable packaging and labelling. The need for novel, advanced drug
delivefY systems is justified by the need to optimize therapy arto circumvent problems
in drug absorption ormetabolism. The sustained-release products were first marketed
during the late 19405 and early 1950$ as a major new class ofphannaceutical product
in which the product design was intended to modify and improve the drug perfonnanc:e
by increased drug duration ofaction as weB as reduced dosing frequency. FolJowing
this, the tetm"controlled drug ddiverJ came into existence in the mid- to late-1960s
to desaibe a new concept ofdosage fonn design which also invoNed controlling and
retarding drug dissolution from the dosage fonn with the additional objectives of
sustained drug action, improved safety, efficiency, andenhanced bioavailability. In the
19705 a new concept of drug product design and administration appeared called the
-U-rapeutic system-. Three types of therapeutic systems have been proposed:
passive preprogrammed therapeutic systems. active externally programmed or
controlled therapeutic systems, and active self-programmed therapeutic systems.
Amongst these three systems the first one which contains a logic element
programmed to a predetermined delivery pattem (mostly constant zero order release)
are already in use. These systems are independent of all the physical, chemical and
biological processes. The second type ofsystems consists of logic elements capable
of receiving and Converting signals extemal to the body to control and property
modulate the drug release from the devk:e within the body. The third type ofsystems
have sensory elements which modulates the drug delivery corresponding to the
infonnation theygatherfrom the biological environment (Banker 1990). Atremendous
amount ofWOlk is presently being done to develop newer dosage forms and perfect
the various existing drug delivery systems in order to meet the g~ng eiinical
demand. A popular and very acceptable delivery system is the transdermal drug
delivery system.
1.1 Transdermal drug delivery systems
There are a variety of routes available for drug delivery corresponding to a
number of biological membranes in the human body: buccal, nasal. and vaginal
mucosa. the gastrointestinal tract including rectum and c:ok>n. the eye and the skin.
Further to this there also exists parenteral delivery, including implants and targeted
delivery. Among all these routes, the transdermal route has received considerable
attention in the recent times due to its convenience, accessibility, and simplicity in
comparison to other routes. The practise of application of drugs to the skin for
systemic absorption and action is an age old approach but has caught more attention
with the introduction and the success ofthe transdermal nitroglycerin ointment products
in themar1c:et.
Transdermal delivery (TOO) can be defined as the delivery of drugs through
intact skin to reach the systemic circulation in quantities sufficient to achieve a
therapeutic dose. Some of the primary dosage forms associated with transdermal
route are: ointments, creams, pastes, plasters, powders, aerosols, lotions, transc:lermal
patches, solutions, and iontophoretic devices (Ansel 1995). With products like creams
and ointments it is more difficult to control the drug dosage, and there is an additional
disadvantage ofsmearing ofthe preparation. In contrast, the transc:lermal patches can
not only lead to a controned release of the drug, but are also relatively carefree with
improved patient ~ceeptabilityover the other conventional transc:lermal dosage forms
such as those mentioned above. Al2A corporation developed the first transdennal
drug delivery patch in 1980 for the systemic delivery ofscopolamine to control nausea,
and vomiting associated with motion sickness. Since then TDO has been recognised
as a viable and attractive dosage form, whose success and acceptability can be
measured by the numerous transdermal products in the market (table 1).
Table 1. Examples of currently marketed tl'anadermal drug delivery systems
ON. Company o..igntype
clonidine Boehringer·lngelheim four layered solid·state
laminate structure
estradiol Ciba-Geigy liquid fonn, fill and seal
laminate structure
etofenamate Bayer semi-solid amorphous
(cream, lotion etc.)
structure
nicotine leder1e peripheral adhesive
laminate structure
nitroglycerine 3M Riker Two layered solid-state
laminate structure
(Cleary 1996)
1.2 Clinically perceived benefits of transdermal drug delivery
There are several dinal benefits associated with mo. It is often associated
with improved patient acceptability over some conventional dosage forms due to the
ease of application and removal otthe dosage form, non·invasiveness. and reduced
incidences of side effects. This non-invasiveness also leads to a reduction in the
infection hazards associated with injection needles. The reduced incidences of side
etreets may be attributed to the fact that with TOO the plasma levels of the drugs can
be maintained at a certain desired level rather than the peaks and valleys seen with
the conventional oral dosage forms. IDD can be tailored to meet the requirements
of individual patients. It also results in the improved blo-availability of some of the
orally administered drugs due. to elimination of variables like hepatic first·pass
metabolism, degradation of drugs caused by the: GIT (GastrcHntestinal tract) pH,
enzymes, etc. Despite all the advantages mentioned above, rnD delivery is feasible
for only a few drugs due to the barrier function of skin.
1.3 The skin and its berner function
The skin is one of the most extensive and readily accessible organs of the
human body. Although it provides a great degree ofphysicaJ protection and integrity,
the principal role of the skin is to keep harmful agents out and water in. The $kin
consists of the following main layers: epidermis, dermis and hypodermis (figure 1).
Most of the skin's barrier resides in the stratum corneum (homy layer): a very
thin (10-15 IJm in thickness) outermost layer of skin. It consists of approximately
fifteen cell layers. The upper 3-5 layers are constantly undergoing desquamation and
are called stratum disjunctum. The lower layers of stratum corneum (stratum
compactum) are thicker, more regularly and densely packed and have resemblance
to the lower viable epidermis. Stratum compactum has higher density of
comeodesmosomes (polar structures interconnecting the comeocytes of the stratum
comeum and contributing to stratum corneum cohesion). These structures need to
be proteolysed for desquamation (Schaefar et at 1996).
Stratum corneum was earlier described as a heterogenous two compartment
--brick and mortar"model. in which the keratin rich cells (comeocytes or horny cells)
are embedded in lipid-laden intercellular domains (Elias 1983). This layer was
considered essentially inert. Later findings showed that Stratum corneum is
catabolically active and that the intercellular domains are basically a heterogenous
mixture of lipids. enzymes. and membrane glycoconjugates, etc.· having both
hydrophilic and hydrophobic lamellae. These findings show that stratum corneum is
not inert (Elias 1991). The interceJlularlipidswith their unique arrangement as ordered
muftilayers have an important role in the barrier's impermeability (Potts et at 1991).
These lipids form the only continuous domain in the stratum corneum and follow a
Figure 1. Representation of the anatomical structures found In
mammalian skin. (The stratum comeum, the outennost layer. provides the
primarytransdermal transport barrier of most compounds. The epiden:nis is avascular
and hence the drugs must reach the circulation in the dermis for systemic
administration.)
tortuous path that penetrates the stratum corneum, a stru<:turaJ feature which
contributes to the barrier properties of the skin. They are mainly derived from
exocyt:osis of the keratinocytes. In the granular layer of the epidermis. the lamellar
granu~move to the periphery of the keratinocytes and fuse with the cell membrane.
Subsequently, the content of these lamellar granules gets discharged into the
intercellularspace. The discharged material in the granular layer retains the shortdisk
like structure which it had in the lamellar granules. However, these disks start to
undergo edge-to-edge fusion and result in the broad, and multilamellar sheet like
structure, that forms a continuous domain, by the time they reach the stratum corneum
(Madison et a!. 1987). Sebaceous secretions a/so contribute to the fonnation of the
intercellular lipids atthough their contribution is much lesser than that derived from the
exocytosis of keratinocytes.
The 100 pm thick viable epidermis (directty bebw stratum corneum) is
responsi)Ie for the synthesis of the stratum corneum. As ·the cells move from the
basal layer to the horny layer there is a shift from the polar lipids to neutral lipids and
almost complete bss ofphospholipids. The conversion into the neutral lipids is a step
toward the barrier formation. The lipid content of the stratum corneum is unique in
ccmparison to the cellular membranes and other epidermal stnJctures. The stratum
eomeumhas 15% water, 70% protein and 15% lipid. Among lipids, ft.hasneutrallipids
(7D-80%), ceramides (15-20%), cholesterol sulfate (2·5%) and has virtually no
phospholipids (Franz et a!. 1992). Feingold and workers have shown that barrier
perturbation results in an increased biosynthesis of sterol and fatty acid in the
epidermis. leading to the lipid replenishment in the stratum corneum. Transepidermal
water loss appears to be the critical regulator of this entire process (Grubauer et a!.
1989). There is a sequential increase in transepidennal water loss as the stratum
corneum is slowly stripped showing that all of the stratum corneum is involved in
providing barrier to diffusion (Bommannan et al. 1990).
The inhibition ofthe enzymes involved in the synthesis ofceramide, ch~sterol,
and free fatty acids leads to an impaired barrier function (Feingold et at 1990, and
Holleran et al. 1993). Hence, the lipid composition of the stratum corneum appears
to be a key determinant of the biological action of this membrane. Recent work has
shown that the aqueous dispersion of ceramide, cholesterol, and palmitic acid
(representing the lipid portion of the stratum corneum) have a complex phase
behaviouras a function oftemperature and pH (Bouwstra et a'- 1997). Such ceramide
dispersions, even in the presence of a considerable mole fi'aeticn of cholesterol, can
fonn crystalline lamellar structures between room temperature and 40°C. The
majority of the crystalline cholesterol is not in a separate phase. Above 40 °C a fluid
lamellarptlase results which is completely reversible with temperature. The precursor
lipids for the stratum corneum (determined by the change in the lipid composition m
the mammalian epidefmis), consist of more typical membrane lipid classes such as
phosphoglycerolipid and sphingolipids (specially sphingomyelin and
monoglycosylceramides). Sphingomyelin under the similar dispersion conditions as
mentioned for ceramides was found to form a fluid lamellar phase. Hence, the
existence of the crystalline structures may be important for unique physical properties
such as epidermal baniar function.
Although the "'tercellular lipids have a major role in the stratum corneum's
impermeability, thft'" role in the tissue cohesion is rmited (Bisset et 31. 1987, and
Chapman etal. 1991). The tissue cohesoo of the horny layer is contributed mostfy
to the intercellular junctions and associated comeocytes (Skerrow et al. 1989 and
lundstrOm etal. 1990). The stratum corneum acts as the rate controlling barrier to the
transdermal permeation of both lipophilic and hydrophilic drugs. 80th proteins and
lipids in the stratum c:omeum could resist drug permeation. The protein and lipid
regions In the stratum corneum form polar and nonpolar pathways, respectivety. The
penneation through the lipid pathway occurs by the dissolution and diffusion of the
drug in the lipids of the stratum corneum. Correspondingty, the permeation through
the polar pathway takes place by partitioning into protein regions swollen by water
(Franz et at 1992). Eartier, Barry had proposed that both the polar as well as
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non~rpathways fordrug permeation reside within the intercelllJlarlipids. According
to him. the dominant pathway of the polarmolecules resides in ttle aqueous region of
the lipids, with the nonpolarpathway residing within the lipid chains ofthe hydrophobic
region (Bany 1987). Recently. using tracers (hydrophilic and hydrophobic) for nonnal.
undisturbed skin and/or after permeation-enhancement (with occlusion, vehicle
enhancers, a lipid synthesis inhibitor. sonophoresis, and ionbophoresis) the pore
penneation pathwayformo~1eswas studied (Menon 1997). It has been found that
regardless of their polarity or the permeation-enhancement method, tracers got
localised to discrete lacunar domains embedded within the e:xtracellular lamellar
membrane system. The discontinuous microdomains, or lacuna... dilatations, arise at
sites ofdesmosomal dissolution within the extracellular lamellae (Hou et al. 1991).
These lacunar domains were discontinuous under basal conditions but appeared to
gain structural continuity with penneation-enhancement by lateral expansion. It has
been proposed that permeabilization results in transient coalescence into an
merconnected network across the stratum corneum. Hence, the extracellular lacunar
domainsappearto comprise the pore pathwayforpermeation ofmaolecules aaoss the
stratumcomeum.
The stratum corneum is considered to have a moktcula. size constraint on
penetration. As the size of the penneant inaeases over 80(1.1000 Daltons the
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penetration of molecules decreases dramatically (Wester et at 1985). The epidermis
has gap (Salomon et aJ. 1988, and Brissette et at 1994) and adherence junctions
(Kaiser et a!. 1993). Gap junctions, thou9h not prevalent. facilitate the intercellular
diffusion of low molecularweight substances which suggests that there is a functional
interconnection between the keratinocytes. There are no tight junctions found in the
stratified epidermis that could prevent the diffusion of molecules. The desmosomes
and adherence junctions form a barrier to the transcellular diffusion of very large
molecules within the epidermis.
Besides the stratum corneum. theepidermis has three other layers. i.e., stratum
basale. stratum spinosum and stratum granulosum. "f!l8se layers represent different
stages of the keratinocytes differentiation and result in the formation of the stratum
corneum. The dermal-epidermal junction is not uniform and in fact. it undulates to
form papillae which inaease the surface area between these two layers. This junction
is made up offoursub-Iayers: intra-epidermal plane. lamina lucida. lamina densa. and
sublamina densa. The lamina densa consists of a dense network of interconnecting
proteins. The lamina densa is attached to the basal keratinocytes with an interacting
meshwork of laminin, entactinlnidogen and fibronectin (Martin et at 1987, Yurchenco
et at 1990) and to the dermis by larger anchoring fibrils composed of type VII
collagen. This dense network of interconnecting proteins reduces the flux of large
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(>40.000 Daltons) but not small molecules. Hence, the dermal-epidermal junction
does not represent the primary barrier to the diffusion of compounds. Below the
dennal-epic:lermal junction is the dermis. This layer fonns the bulk of the skin and
determines its tensile strength, elasticity, and provides physical support for extensive
nerve and vascular networks. Appendages that originate from the dennis often
penetrate into the horny layer and represent the sites for penetration ofdrugs into the
body. The appendages like hair follicles and sweat glands are srtes of physical
discontinuity in the stratum corneum which serve as a penetration pathway. These
appendages account for only 0.1~1% of the surface area of the skin and only 0.01-
0.1% of the skin volume. These shunt pathways are belIeved to be important for
molecules which have a slower percutaneous absorption and are believed to play an
important roM! in iontophoretic transdennal transport. The vascularnetworkofthe skin
does not reach the epic:lermis. As a result, the drugs need to reach the vasculature
in the dennis for systemic absorption. Undertying the dennis is the hypodermis which
is basicaDy a layer of adipocytes arranged in 5obu1es. The intracellular fat droplets
here may act as a depot for hydrophobic compounds that penneate the stratum
corneum and pass the vascular netwonc: in the dennis without getting absorbed.
However, the hypodermis has an extensive vascular network and hence molecukts
reaching it can be considered as getting distributed throughout the body.
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Skin has a refatively lipophilic stratum corneum and a relatively hydrophilie
viable skin (epidermis and dermis). Hence, partitioning of a hydrophilic drug into the
stratum corneum and partitioning of a lipophilic drug out of the stratum corneum and
into the dermis arethe rate determining steps for skin penetration. Besides the stratum
corneum, proteolytic enzymes in skin form the other majortransdermal delivery barrier
which could inactivate some peptide drugs like enkephalins, insulin, etc. Proteolytic
enzyme activity including leucine aminopeptidases. and endopeptidases is present in
the Triton X-1 00 extracts of human skin fibroblasts (Homsy et al. 1988). Amidon and
cowor1<ers reported that at neutral pH, the enzymatic activity in the skin was so strong
thatthey observed no flux ofleucine-enkephalin in the receptorcompartment, whilethe
donor concentration also decreased very rapidly (Choi et al. 1990). This suggests that
the enzymatic barrier of the skin cannot be completely undermined as such while
planning transdermal delivery for peptide and protein drugs.
1.4 Transdermal drug delivery enhancement
TOO delivery is onty feasible for a few drugs due to the barrier function of skin.
Generally small, potent, uncharged and lipophilic molecules, but with a certain degree
ofwater solubility, are good models for transdermal delivery. To extend the spectrum
of drugs that can be delivered transdennally, a number of enhancement techniques
have been tried out:
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1.4.1 Chemical enhancers
Franz et aJ. have defined chemical enhancers as compounds which by their
presence in the stratum corneum are able to alter the flux of the desired drug either by
alteration of the strabJm corneum structure or by increasing the drug concentration in
the skin (Franz et at 1992). In addition to enhancing the delivery of the drug, the
enhancer needs to be systemically nontoxic, nonirritating and should not produce any
pharrnac:::obgical responses. Its actions are expected to be reversible, prompt, and
with a predictable duration of action.
Firstancl foremost, hydration ofthe stratum corneum such as that caused by the
occlusive transdel"nl4ll patches has been shown 10 result in the decrease in the barrier
function in a majority of cases. This has been well demonstrated in the case of many
penetrants, including esters of salicylk: acid (Wurster et al. 1961), and corticosteroids
(McKenzie et al. 1962). Additionally,sodium pyrrolidone carboxytate which is believed
to be the principal humectant in its rote as a natural moisturizing factor for the skin
(BaITY 1983) has been tried out for its posstlle role in enhancing the skin transport of
molecuJes. Although the et'l'ectiYeness of this molecule in transdennaJ delivery
enhancement has not been as encouraging, its analogs i.e., 2·pyrrolidone and N·
methyl-2-p~idonehave shown to increase the transport of steroids (Bennett et al.
1984) and aspirin (Southwell et at 1984). Besides hydration, a number of solvents,
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detergents. oils etc have been tested fortheirenhancement property. Surfactants like
decylmethyl sulfoxide are known to ad preferentially as enhancers on the polar
pathways (Cooper 1982). Azone (1-dodecytazacycloheptan-2-one; laurocapram) has
been shown to be a very effective enhancer ofskin permeability. In fact this molecule
had been designed and synthesiZed specifically for this purpose. Alone is believed
to ad by an ion-pairing mechanism for the permeants and a single dose of azone is
capabkt of enhancing the aubsequent doses of penneant for at least 5 days. This
molecule is effective enhancer ofa number of hydrophilic and hydrophobic molecules
(Stoughton et at 1983). Addrtionalfy, unsaturated fatty acids like cis-9- and cis-
11~decenoic acids (Golden et al. 1987) and short chain alcohols like ethanol
(Ghenem et at 1987) generally result in the enhanced penneation of lipophilic solutes.
The usefulness ofethanol as a penneation enhancerhas been demonstrated by its c0-
administration with estradiol (Campbell etaI1934). In fact, due to fears oftoxieity. only
ethanol has been approved as a chemical enhancer by the Health Protection Branch
(HPB) tift now. The chemical enhancer.> are believed to mainly act by disrupting the
stratum corneum lipid structure (Hadgraft et at 1989 and Smith et at 1995).
Interestingty. the transdem1a1 delivery of lipophilic molecules has also been shown to
be enhanced by incorporation in liposomes. The topical application of the drug·kladecl
liposomes promotes delivety of the active ingredient to local tissues and, may also
reduce systemicdrug levels. The result of the topical application ofliposomes was first
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reported by Mezei and Gulasekharam (1980) in which triamcinolone acetanide
entrapped within dipalmitoylphosphatidylcholine-cholesterol multilamellar vesicles
resulted in significantly enhanced drug levels in the rabbit dermis and epidermis along
with reduced blood and urine levels. Similarty, lidocaine applied on the forearm of
human volunteers has been found to produce greater local anaesthetic effect in the
Iiposomal form than in the cream form (Foldvari et at 1990). A number of parenteral.
Iiposomal formulations are presently in clinical bials. The rapid progress in Iiposome
technology that has been made in the past few years suggests that topical liposomal
products have a promising Mure.
1.4.2 Physical enhancers
Some of the physical enhancement techniques like iontophoresis,
phonophoresis, and electroporation have also been tested for delivery enhancement
Another physical enhancing method which was also tested eanier involves the
controlled removal of the stratum comeum using pulsed laser light. The stratum
corneum is removed without a significant damage to the undertying epidermis, with the
use of a proper wavelength, pulse-tength energy, and pulse rate (Nelson 1990).
1.4.2.8 Iontophoretic transdermal drug delivery
A lot of work has been done on the transdermal drug delivery enhancement
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using iontophoresis. Iontophoresis has been defined as the ·process or technique
which involves the transport of ionic (charged) molecules into the tissue by the
passage ofa direct electric current through an electrolyte solution containing the ionic
molecules to be delivered using an appropriate electrode polarity" (Banga et at 1988).
Iontophoresis has the advantage that it can be used to deliver ionic drugs, which have
a poor passive transdermal absorption and require chemical enhancers which can be
irritating or sensitizing to the immune system. The driving forces for the iontophoresis
of charged molecules are believed to be electrorepulsion and electroosmosis.
Electrorepulsion involves a charged drug dissolved in an electrolyte solution
surrounding an electrode of similar polarity and when electromotive force is applied.
molecules get repelled into the subjacent tissue. The iontophoretic delivery of neutral
molecules is intrinsically linked with electtoosmotic water flux (Gangarosa et al. 1980.
and Srinivasan et 811. 1989). The major pathways for iontophoretic drug delivery are
believed to be appendageal pores including the sweatduets and hairfollicles (Burnette
1988). A dot...jike pattern overthe sweat gland openings has been observed following
the iontophoresis of a charged dye in human skin. showing the contribution of the
sweat glands in iontophoretic drug delivery (Abramson et a!. 1940). Lee and
coworkers observed that in case ofcultured skin models, which have no appendages,
the paraceUular route provides the path of least resistance to ions traversing the skin
(Lee et al. 1996). However, they also found that the appendageal routes form the
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major transport pathways in hair1ess mouse skin. Iontophoresis is used in the
tre.bnent of hypertlydrosis (Grice et aL 1972. and Sloan et al. 1986) and for the
diagnosis ofcystic ftltosis (Gibson et al. 1959). lontocaine·, an )ontophoretic system
for the transdermal delivery of lidocaine has been recently patented by lomed Inc.
Iontophoresis is being presently studied foe transdermal delivery of a number of small
drug molecules foreommercial use. HO'INeVer, the success ofthe iontophoreticdelivety
of large-molecular-weight compounds such as peptides remains elusive because the
enhancement produced by iontophoresis is generally insufficient for macromolecules.
1.4.2.b Phonophoretic transclerrnal drug delivery
Phonophoresis (sonophoresis) invoNes the application ofultrasound energy for
enhancing transdermal drug delivery. The mechanical energy used in phonophoreSis
is obtained bypassing altemating currenttluough a piezoelectJiccrystal, which causes
it to vibrate. Physical therapists use uttrasound iordelivering topical anti-inflammatory
or kK:al anaesthetic agents, and forI~procedure (Barnett et al. 1994, Stewart
et at 1983. and NCRP Report No. 113). Clinically it is used at dose intensities below
2 W/crrf. treatment duration ranging between 5 and 20 min and with frequencies
usually lesser than 3 MHz. Phonophoresis has been used for the past fifty years.
however recent studies. that demonstrated therapeutically relevant delivery of
macromolecules with phonophoreais, have spal1c:ed a renewed interest (Mitragotri at
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at 1995a). Ultrasound produces two kinds of etrects on tissues - heating and
cavitation. In order to avoid over-heating, ultrasound is applied under therapeutic
conditions. VVhen used at lesser frequency or greater intensity than therapeutic,
ultrasound leads to excessive generation of gas bubbles often referred to as the
'cavitation effect'. The cavitation effects can lead to significant changes in the
biological tissues such as the skin. There is no agreement on the possible mechanism
of phonophoretic enhancement. It is generally believed that the thermal contribution
is limited. However, evidence of increased convection (e.g., acoustic mixing) and
cavitation mediated effects are possible explanations (levy et al. 1989. and Mitragotri
at at 1995).
1.4.2.c Bedroporative transdennal drug delivery
The application ofeIectroporation in transdennal delivery has been very recent
(Prausnitz et at. 1993). Electroporation has been defined as a method for reversible
permeabilization oflipid bilayers, involving the creation of transient aqueous pores, by
the appfteation ofan eiec:tric pUlse. Permeability and the eiectrical conductance of the
lipid bilayers (inetuding living cells, .rtificial spherical and pUlnarsystems) is increased
by many orders ofmagnitude. ElectToporation appears to be universal in lipid bilayers,
with onset independent of their exad. composition or structure. In fact. prior to the
recent (5 years ago) transdermal application. electroporation was already being used
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tOt'" a number of purposes including the enhancement of the uptake of molecules by
cells and tissues. For instance. eIectroporation is being widely used in molecular
biology as a method for gene transfection by introducing DNA into cells (Neumann et
at 1989, and Chang at at 1992). The transdennal work by Prausnitz and co-workers
(1993) was the first application of electroporation to a multilamellar and non-
phospholipid system.
There existsa clinical precedentforsafelyapptying eiectrical pulses ofhundreds
of volts with a duration of up to milliseconds to the skin. There are a number of
diagnostic and therapeutic applications. which while causing nerve stimulation also
lead to electroporation. These include: somatosensory-evoked-potential testing.
electromyography.funetionalelectricalstimulation. and transcutaneouseledrical nerve
stimulation (Prausnitz 1996b). EIectroporation has abo been used in combination with
chemotherapy (electrochemotherapy) for potentiation of the antitumour effects of
intramusctJlar1yadministeredbleomycin in nude micewfth subcutaneouslytransplanted
tumours (Miret at 1991) and in C3HJBi mice with spontaneous mammary carcinomas
(Belehradek et at 1991). In the subsequent clinical phase 1·11 trials, electrical pulses
were applied to permeation nodules of head and neck squamous ceO carcinomas in
patients to increase the uptake of the intravenously administered bolus doses of
bleomycin (Belehradek et af. 1993). The absence of toxidtY', good tolerance by
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patients, and net antitumour effects (57% nodules had a complete cfinical response)
encouraged further work. RecenUy, intralesional bleomycin mediated
electrochemotherapy was tried out in 20 patients with basal cell carcinoma (Glass et
at 1997). In all, electrical pulses were delivered to 54 tumours. Complete responses
were observed in 53 (98%), and in majority ofthese (94%) after a single treatment with
no recurrences with around 18 months of observation.
BRsjl for the appljcation of eloctropol'ltipn jn gn."",! drug delivery
The stratum corneum Is • very thin layer with a very high resistance (resistivity
in the range of 100-5000 kO.cm~with the underlying skin exhibiting a much lower
resistance (resistivity around 0.1- 1.0 kO:.an2) (Chien et ar. 1993). This difference in
the resistivity Is expected to resutt in the concentration ofthe applied electric field in the
stratum corneum, with the other viable tissues exposed to much lower fields. Hence.
a field that is sufficient to cause eiectroporation in the stratum corneum may be
present, while a significantly lower field exists in the viable tissue which is insufficient
to electroporate them. Thus, it would seem that a natural targeting mechanism is
present where the greatest ektctric fields and perturbation occurs in the layers where
the greatest resistivities exist, and at the same time the already permeable and viable
parts of the skin would be affected Yef'f little.
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The ektctroporation thresh<»d for a single bilayer is in the order of 1 V (Tsang
1991 and Weaver 1993). Prausnitz and co-workers note that the presence of a few
hundred bilayers in the stratum corneum should then result in a threshold of a few
hundred volts, up to which long lasting changes in the skin should not be observed
(Prausnitz et aL 1993). Their ifl.vitrD data suggests that pulses at or below 100 V
(transdermal voltage) caused no long lasting changes in the skin. VYhereas voltages
higher than that result in changes in the skin that do not go tNl8y even after 18-24
hours. Additionally, their in-vivo work has shown that the fluxes did not increase with
increasing voltage, suggesting that the rate-limiting step is not affected (or influenced)
by applied voltage. This is in contrast to the in~vitrodata, where the transdermal drug
delivery is seen to keep increasing with an increase In the applied voltage.
Vanbever and ~ers have shown in their eartier in-vitro work that it is
possible to enhance the transdermal delivery of metoprolol using electroporation
(Vanbever et at 1994). They found that the delivery of metoprolol is affected by the
voltage, pulse length ('t), and number of Pulses. A small number of low voltage long
duration pulses were more efficient than a large number of high voltage-short duration
pulses (Vanbever et at 1995). Similarly, wortl: has been done on the transdermal
delivery of fentanyt whteh has shown that the wave form of the electric pulses is very
important (Vanbever et al. 1996). At. Ule same applied energy, the fentanyl
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permeation-enhancement was greater with exponentially decaying pulses than the
square-wave pulses. Vanbever and C().Workers reported that electrophoresis and
diffusion through highly permeabilized 5100 led to a rapid transport. during pulsing and
according to them no efectroosmosis OCClJrs during electroporation (Vanbever et al.
1996a). If electrophoresis is assumed to be involved in eIectroporative bansdermal
drug delivery then the physicochemical properties of the molecule being transported
8$ well as the solution would be vefY important in drug delivery. Hence, care needs
to be tajc;en in choosing the formulation used for eMK:troporation. Recent in-vWo
delivery studies done by the same group have shown the potential of sldn
electroporation in rapidly achieving significant plasma levels of fentanyl in rats
(Vanbeveret al. 1998). The onset ofanalgesia was expedited to a few minutes by high
voltage pulsing compared with the several noursonset time seen with passivedelivery.
The onset of analgesia seen after etectroporative transdermal fentanyt delivery was
even more rapid than by iontophoretic delivery. 'The skin tolerance was examined
visually and scoring was done after pulsing {voltage values reported being U....-J at
15 pulses of 100 V-500 ms, 15 pulsesof250V~200msand 60 pulses ofSOOV·1.3 ms.
250 V appeared to cause a slightly increased redness while neither iontophoresis nor
pulsing at 100 and 500 V seemed to induce erythema. It is very important to note here
that the absence oferythema at 500 V is not surprising fookjng at the very small pulse
length used compared to the prolonged pulse tength used for 100 and 250 V. It has
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been reoentty reported that the application of long eIectroporation pulses led to a
decrease in the intensity of the lipid peaks observed in SAXS (Small Angle X-ray
scattering) and WAXS (Wide Angle X-ray scattering) as opposed to short pulses,
indicating that both inter1amellar and intralamellar structures were being affected
(Jadoul et a!. 1997). Correspondingty. 60 pulses of 500 V-1 ms caused onty a slight
decrease in the intensity values observed with SAXS and WAX.5. In a separate study
done using pig skin. it has been shown that when a single pulse with a U_ of 0
(control), 500, Of 1000 V was administered before a eurrent density ofeither 0.4 01'0.8
mA/r;rn2was applied for 30 minutes, erythemaand edema (mostsevere at 0.8 mAlcnr)
were observed at all pulse vottage values (Potts et at 1995). Gross and light
microscopic evaluation showed that eIectropofation did not cause any skin damage
that has not been seen with iontophoresis alone. The onty detmal alterations that were
seen with eIectroporation are mild intraepidermal vacuolization and a transient
erythema.
Prausnitz: and coworkers have shown that eledroporation ~s to a rapid
transdennal transport involving steady state lag times and onset time ofminutes which
indicates that rapid temporal control of transport is possible (Prausnitz et al. 1994).
Transdennal delivefy enhancement ofdrugs through the skin has been shown to occur
with each pulse (Chen et aI. 1998).
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1.5 EnMncement techniques used in conjunction with e5ectroporation
The permeability barrier of the skin is very high for a number of drugs. To
overcome this barrier, a strong physical force such as electroporation needs to be
used. The strongest of these forces that can be used is likely to be limited by their
adverse physiological effects. For instance, electroporatiYe pulsing conditions such as
voltage, pulse length and pulse numbercan only be increased fortransdennal delivery
enhancement to a point. beyond which it may be hannful. This forms the limitation of
eleeuoporation in transdermal dnJg delivery. Many of the transdennat drug delivery
enhancement techniques have a different route of action and hence if used in
synergism may be more effective, while being safe. Some of the different techniques
hied out in conjunction are described below:
1.5.1 Iontophoresis and electroporation
Although both iontophoresis and eectroporation involve eMK:tric fields, their
basic mode ofaction diffefs (prausnitzetal. 1993). Iontophoresis basicalty acts on the
drug and moves the molecules across the skin surface by electrophoresis and/or
electroosmosis. Any changes that occur in the skin structure occur only 8S a
secondary effect (Hadgraft et at 1989). However, electroporation causes large
changes in the permeability and the conductance of the skin. Hence, for
eiectroporation the e'ectric field is believed to act by aeating aqueous pores in the skin
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and molecules are speculated to move through these pores by diffusion,
electrophoresis and/or electroosmosis. It has been recently shown that there is no
iontophoretic enhancement ofdrug delivery when black rat snake skin was used in the
in·vffro studies as opposed to the human skin (Chen et at 1998). However, the use
ofektctroporation caused an enhanced drug delivery with both snake and human skin
samples in the same study. Snake skin lacks hair follicles while iontophoresis is known
to cause transport through hair follicles and sweat ducts. This explains the absence
of iontophoretic delivery in the snake skin. This also shows that iontophoresis and
eIectroporation have drtrerent routes ofdrug delivefy. As has been mentioned earlier,
the route for iontophoretic drug delivery is believed to be appendagea!. Recently, it
has been shown that electroporative transdermal delivery occurs through localized
transport regions (UR) in the epidermis which do not correspond to the appendages
(Pliquett et al. 1996). Interestingly, the LTR's have been found to be localized in the
area of the heat-stripped skin corresponding to the dermal papillae (troughs of the
epidermis) and no lTR's appeared in the Rete pegs (crests of the epidermis). After
applying lower voltage pulses (transdermal voltage < 80 V) the edges show more
fluorescence. than the interiors of the keratinocytes in the l TR·s. However, after high
voltage pulsing (transdermal voltage> 160 V) the ffuorescence of the edges and
interiors of the keratinoc:ytes are indistinguishabie. This shows that pulsing at high
vobge was found to resort in the creation of the aqueous pathways that pass through
27
the keratinocytes. The l TR's were found to occur at and above the transdermal
voltages of 75 V. The numberof l TR's were found to increase with the increase in the
applied voftage (between 75 V and 160 V) but in spite of the voltage used, their
apparent initial diameter was 10 IJm. An increase in the numbef"ofpulses increased
the diameter of the l TR's to apprarinately 40-80 fJOl. It is important to note that the
increase in the number of LTR's created after the third pulse at a constant voltage was
very limited.
Work has been done to compare the ;~vitro tranadermal delivery obtained by
iontophoresis alone, with the delivery seen with iontophoresis following a single
electroporation pulse (Tamada et al. 1993). The latter had a significantly increased
delivery as compared to iontophoresis alone. This shows the potential of combining
these two techniques for drug delivery enhancement
1.5.2 Chemical enhancers and alectroporation
It has been found that the transdermal eIec:troporative delivery of a highly-
charged macromolecule (heparin) remained partially eJevated fOf several hours after
high voltage pulsing (Prausnitz at al. 1995). Most heparin molecules are bog enough
to span the five to six ~ipid bilayer membranes that separate comeocytes within the
stratum corneum. Hence it is quite possible for a finear macromolecule such as
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heparin to enter the aqueous pathways created by the high voltage pulsing and after
the flux of the smaller, co-transported ions and molecules by either inaeasing the
pathway life time or providing charge within the pathway that can attracVrepel co-
transported species (Weaveret at 1997). This "foot in the door" hypothesis has been
proposed even for some single bilayer membranes such as those inYOlYed in the cell
membrane electroporation evveaver 1993 and Sukharev et al. 1992). The possibility
of heparin getting entrapped in the transport pathways while further enhancing
transport delivery comes from the fact that heparin did not enhance the passive or
iontophoretic drug defivery.
In the wor1t mentioned above, heparin is enhancing its own transdermal
eJectroporatiYe drug delivery due to its "foot in the door" action. Besides heparin, a
numberofother macromolecules I.e., dextran-sulfate, neutral sutfate. and poIy.lysine
have also been tried out as elec:troporative transdemlal transport enhancers for
mannitol Nanbeveret al. 1997). Eledroporation by itseff enhanced the transdennal
delivery of mannitol by approximately two on:fefS of magnitude white the presence of
a macromolecule enhanced the delivery of mannitol up to five fold. Macromolecules
with greater charge and size have been found to be more effective in enhancing
transdermal transport. ThesemacromolecularchemicalenhancelS differfromthe ones
that are utiliZed in the passivede'ivery. The traditionalfy used chemical enhancers like
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ethanol. azone. DMSQ etc are believed to wortc by disrupting the stratum corneum lipid
structure. However, the macromolecules act mainty by stabilizjng the transient
disruptions already caused by the electroporation of the skin. Ethanol. a traditionally
used enhancer has been tried out for enhancing the transdennal delivery of
cycIosporin-A (CSA) in combination with iontophoresis and electroporation (Wang et
at 1998). It was found that enhancement of CSA's transdermal permeation, both by
ethanol alone and in combination with iontophoresis was inadequate for transdermal
delivery. However, In the presence of ethanol. multiple electroporative pulses (>10)
resulted in a sixty fold increased delivery of cydosporin in the skin. Hence, use of
chemical enhancers in combination with Nctroporation appears to hold a potential for
h.igher transdermal drug delivery.
1.5.3 Ultrasound and eIectroporation
The application of ultrasound in the presence of etedropofative pulsing has
been found to enhance the transdennal flux ofcalcein and sUlphortlodamine by 2 and
3 times respectivety, as compared to delivery by electric putsing alone (Kost et at
1996). The lag time for drug delivery is also reduced by this combination. Ultrasound
application also reduced the threshold voltage required for the onset of calcein and
sulphortlodamine transport in the presence ofelectric fields. Application ofultrasound
induces cavitation in the keratinocytes of the stratum corneum. The oscillation of the
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cavitation bubbies has been shown to induce a partial disorder in the skin lipid bilayer
(Mitragotri et 81. 19958). The electrical resistance of the disordered bilayers is less
than that of the nannal bilayers hence the applied electric field would preferentially
concentrate across the normal bilayer. This decreases the threshold eIectroporating
vottage fortransdermaJ transportofcompounds. Hence. the combination ofultrasound
and electroporation is another viable option for higher transdennaJ drug delivery.
1.5.4 8ectroincorporation
EIectroinCOfPOllltion has been defined as the transport of substances by mass
transport of microcarriers through a biomembrane (Hofmann et at 1995). Carriers
such as vesicles can migrate through the stratum corneum as a~ by eM!ctro-
incofporation. Hence. the drug that needs to be delivered is encapsulated into a
microcarrier. These microcarriers are brought in close contact with the skin. A field
with components perpendicular to the stratum corneum is created by the electrodes
on top of the microcarriers whld, results in the transport. The encapsulation of the
drug in the microcarriefs is supposed to protect the sensitive drugs from enzymatic
breakdown and hence result in an improved drug delivery.
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II. RESEARCH PLAN
The application of eiectropolation in the field of transdennal drug delivery
enhancement has only recently been explored. Electmporation involves the
application of high voltage pulses of a few ms duration to the skin. Although the
knowtedge in this fie$d is rapidly expanding there are still many unanswered, or
incompletely answered questions. The influence ofelectrode design has not yet been
studied yet as a parameter influencing eIectroporative drug de4ivery. There also exists
a need to study the macroscopic or microscopic changes in the skin due to
eJectroporation and to establish the safety of the technique tor any such application.
Hence, the ove,.n objective of this Protect was to study the parameters invotved in
the electroporative transdermal drug delivery technique so as to optimize its efficiency
and safety. The speciftc objectiv.. of the research were to:
1. optimize the basic parameters of ~rative transdennal delivety using a
fluorescent drug terazosin hydrochloride (TRZ) as a probe, under varying conditions
of applied electrode voltage (U--> & voftage drop across the skin (U->, pulse
lengths and number of pulses and electrode area.
2. study the safety of the technique by:
a) studying the recovery of skin's banier property at the different eJeetroporative
conditions.
b) studying the histological changes in the skin after using different e4ectroporation
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pulsing conditions.
c) detennining the energy delivered to the skin at various electroporative conditions so
as to get an insight to the processes and mechanisms. This would be done by
measuring various efectrical properties of the skin during pulsing.
This research project was based on the ~Iowing hypotheses.
1. Use of electroporation would enhance the transdermal delivery of the model drug
TRZ as compared to its passive delivety.
2. The efficiency and S8fety of the tedvliquewoukl be dependent on eIectroporation
parameters such as voltage. pulse length, number of pUlses and electrode area.
3. By aIIering the above parameters it would be pos.si:IM: to achieve an etfedive
transdermaJ ~ivery with minimum damage to skin, thus ensuring safety of the
technique.
33
I
I
I
I
I
I
I
I
I
V. MATERIALS AND METHODS
5.0 Materials
5.1 Chemicals
Terazosin hydrochloride [1..(4-amin0-6.7~imethoxy-2..quinazolinyl)-4-{2­
tetrahydrofuroyOpiperazine hydrochloride dihydrate] was provided by Abbot
Laboratories, ce, Canada (Mol. YIlt otTerazosin: 387.44). prazosin hydrochloride [(1-
(4-amin0-6.7-dimethoxy-2-quinazolinyl)-4-{2-furoyl) piperazine hydrochloride
monohydrate] was used as an internal standard and was obtained from Sigma
Chemicals Co.• MO, USA All other solvents and reagents used were of HPlC and
analyticalgrade. Purified water was obtained using the Barnstead Nanopure II system
(Bamstead, MA, USA).
5.2 EJ8ctroponJtion set-up
Gene Pulse'-'I (Bio Rad. CA, USA) fitted with Ag/AgCI electrodes was used as
the source for generating single and multiple exponentially decaying electrical pUlses
for efectroporation. Custom made AglAgCI e*:trodes were used to replace the
shocking chamber that comes attached to Gene Pulser-II. The Gene Pulse'-11 unit
was equipped with a capacitance extender. a pulse controUer unit and a panel that
displayed the values of appled v_ (U-l, pulse length «), capacitance, and
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resistance (sample + system). U_can be defined as the peak value of voltage of
an exponentialty decaying electric field apprl8d between anode and cathode dUring
pulsing. Similarty, ~ can be defined as the time required for the applied vottage to
reduce to 37% of its original value. The vobges generated from the electroporator
were verified using a TektronOC- ~5111 storage oscilloscope (Oregon, USA) for
determining the accuracy of the output pulses in comparison to the values displayed
on screen. The storage oscilloscope was also utilized for measurement ofthe vottage
drop (U.J across and through the skin. Probes-10X (Fluke--Phillips) were used to
assist in these measurements, by reducing the output 10 times, as the transdermal
vottage drop was in some cases beyond the normal range of the TektronO:- -5111
storage oscilloscope. The probes appended to the oscilloscope were calibrated using
an Eppley Standard Cell to ensure that they accurately reduced and transmitted the
output voltage to the osalloscope.
5.3 Electrodes
AglAgCI electrodes, made from a silver wire (1.0 em in diameter, purity: 99.99+
%, Aldrich-Chemical Co.• WlS, USA) byelectrocoating withAgCI on thesurlace, were
used as both anode and cathode in electroporative TRZ delivery experiments. The
influence of the electrode area on the values of U_ was studied by replacing the
normally used small electrode (area s 0.56 ctn~ with a large eIedrode (area"" 2.74
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cm2) and measuring the values of U...... achieved after pulsing. The silver wire was
spiralled to form a Joop for increasing the surface area of electrodes. For all these
experiments an identical silver wire with a diameter of 0.5 mm was used.
5.4 HPLC analysis
The analysis of the TRZ samples was done using an HPLC system that
consisted of a Waters- Model 510 HPLC pump (Waters associates. MA, USA), a
Shimadzu SIL-9A autoinjector and RF-535 Fluorescence HPLC monitor (Shimadzu
Corporation, Kyoto, Japan). The fluorescence detector was set at an excitation
wavelength of345 nm and an emission wavelength of400 nm. The analytical column
was a Waters- ReM 8 x 10 cartridge.packed with Nova-Pak C18 reverse phase
particles, fitted with a Nova-Pak C18 guard column. Responses were recorded as
peaks on an L.KB 2210 (Bromma, Sweden) recorder operated at the speed of 10
mmlmin. The mobile phase consisted of phosphate buffer (pH 7.0), acetonitrile and
tetrahydrofuran in the respective volume ratio of 76:18:6. The mobile phase was
clarified and degassed by littering through a 0.22 .,.m membrane filter, at least twice
(Millipore Corporation, MA, USA) and was pumped isocratically at a flow rate of 1.0
mUmin. Accu~- model 10 pH meter (FISher Scientific, PA, USA) was used to
measure pH of the solutions.
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5.5 Animals
Seven to eightweeb old hairless rats were initially procured from Charles River
Laboratories, QC. Canada. However, at a later st;age for reasons beyond our contra(
the animal supplier source had to be changed to Harlan Sprague DawieY. IN. USA.
The excised skin from the two sources were compared with regard to electrical
resistance and were found to be similar. However, in order to maintain uniformity of
skin source all the drug transport experiments were performed using the Charles River
Laboratories rats and all the experiments for measuring U_ were performed using
Hanan Sprague Dawley rats.
5.6 Diffusion'cell assembly
For the drug deiivery studies, a custom designed side-by·side diffusion unit
(figure 2) made of Delrio (Pofymethanal. Duponr-, was used. The distance between
the two electrodes during pulsing was 10 mm. The effective diffusional cross section-
area of the cell was 1.3 em'. Isolated sk:in was sandwiched between the donor and
receiver compartments with the stratum correum side of the skin facing the donor
side. The anode was inserted in the donorcompartment which contained TRZ solution
(1.03 mglmL) in phosphate buffered saline (PBS, pH 6.4). The cathode was placed
in the receiver compartment during pulsing and contained the PBS. All experiments
were performed at room temperature (22 :t 1 • C).
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5.7 Four electrode assembly for U.. det9fmination
For determining the U__ vs U...... relationship, custom designed side-by-side
cells (figure 3) made of P.xiglass· (Room and Haas Co.• PA. USA) were used. This
material has the advantage that it is transparent and allows easy viewing of the
contents. These ceUs had the same cross-sectional area as the diffusion cells used
for drug delivery, viZ. 1.3 cmZ. The cells had three holes for the placement of the
pulsing electrodes, so the distance between the two pulsing electrodes could be varied
between 10 to 20 or 30 min. Besides having holes for placing the delivery electrodes.
each ofthe chambefs had holes very dose to the open end of the ehamber(2 mm from
the skin when assembled). through which l-shaped Teflon- tubes (Haber-luggin
capillaries) were inserted. The open end of the tube just touched the skin in the
assembled unit The Tefton· tube (0.03- Internal Diameter and 1/1a- Outer Diameter)
was filled with agar-KCI gel and AglAgCI electrodes were inserted in the gel. These
two InnerAg/AgCI electrodes were connected to the oscliloscope to record U....... while
electroporation pulses were delivered from the outer electrodes.
5.8 Choice of TRZ as th9 model drug
One ofthe challenges in transdennal drug delivery research is the development
of a suitable analytical method to accurately quantify drugs in the skin. Organic
subst8nces such as lipids and enzymes from the skin interfere with drug separation
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and analysis. Selective extraction ofa drug is often complicated and so is the analysis
of its extract using HPlC with a UV detector. This problem coukf be best solved by
selecting a radiolabeled or a fluorescent drug molecule that could be detected using
an HPlC system coupfed with a radiometric or fluorescent detector. TRZ, a
fluorescent molecule, was chosen as the model compound for the initial optimization
experiments. TRZ can be easily and accurately analyzed using HPlC equipped with
a fluorescence detector (Singh et aI. 1996). UseofTRZas a model probe served the
purpose to conduct optimiZation experiments and to get a better understanding of
permeabilization of skin using e6ectroporation.
5.9 Control
The control study consisted of the passive diffusional delivery of TRZ. All the
conditions for control delivery, including the donor and receiver solution composition
were kept the same as that in the electroporation experiments. In the pulsed samples,
eMctroporativepulses underspecified conditions were u$8d forenhancing the delivery
of the drug whereas in the case of the control drug delivery was by passive diffusion
and theretore unassisted. Control experiments were performed with eaen set of
electroporation experiments.
5.10 EJectroporation experiments
The rats were sacrificed using a carbon dioxide chamber. Full thickness
abdominal and back skins were excised and used within 8 hours. Subcutaneous fat
and musde 1a)'8f$ were carefully removed from the skin. The excised sJdn samples
were hydrated by soaking for 2 hours in PBS. Skin samples were sandwiched in the
diffusion cell (figure 2) between the donor and receiver compartments. The stratum
corneum side of the skin faced the donor chamber. Skin samp*> having resistance
bekM' 20 KQ were discarded. The kJwrered resistance cook! be due to any damage
inherently present in the rat skin or inflicted to the skin during its preparation, which
may have rendered the skin 'leaky', resulting in the Jaw resistance. Exponentially
decaying electroporation pulses were delivered using the Gene Pulse'-U unit with
AglAgO electrodes. Murtiple pulses were deWered with one minute interval between
each pulse. The pUlses were characterised by the applied electrode voltage (U->,
the number of pulses, and the decay time constant of the applied exponential pulse,
I.e.. the pulse Iongth «).
5.10a TRZ deliverY across the skin o\l'8r 8 h period
Samples of 1OO.,.lwerewithdrawn from the reoeiverchambers atdifferenttimes,
viz..O, 15, 30, 60. 120, 180, 240, 300, 360. 420, and.so minutes. Immediately after
withdrMng samples. an equal amount of PBS was added to the receiver side to
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replenish the volume 5os$. Samples were anatysed using HPlC. The decrease in the
concentration ofTRZ in the receiver side due to the sampling was acecunted for while
calculating the amount of TRZ recovered in the subsequent sampleS.
5.10b. TRZ delivery in the skin tissue
The amount ofTRZdefNered into the skin soon afterdelivery ofthe pulses was
quantified in a separate set of experiments performed using a similar set-up as
described above. After pulsing, samples were withdrawn from the receiver side. The
eerts were emptied, dismanUecl, and skin specimens were removed. The stJatu'n
corneum side of the skin was washed with deionized water 3 times and Scotch-
adhesive tape (3M, Ontario, Canada) was used to strip It 3 times to remove any
superficially attached drug. The SCotch- tape strippings were coHected in metha~
solution, and extracted. The extrad was analysed to account for the amount of drug
removed in the strips. A biopsy punch was used to cut out 0.87 anzof the skin sample
to quantify the TRZ delivered in the skin. This sample was stored in 1 mL ofmethanol.
An appropriate amount of prazosin solution was added to the solution, and the skin
sample was homogenized using a Brinkmann homogenizer (Potytron-, Switzerland).
It was further extraded using 3 x 1 ml of methanol and centrifuged. The combined
extracts were centrifuged and anatyzed using HPlC forthe TRZ content The amount
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of drug delivered into the receiver side was also anatysed. The influence of various
pulsing parameters like U--.... 't, and number of putses on the transdermal delivery
ofTRZ were studied to detennine the optimal pulsing conditions.
5.1~ Reversal of the petrrJelJ!Jl7;ty enhancement caused by electroporation
This experiment was designed to assess the reversal of the electropor8tiorr
induced penneability..enhanc:ement in skin. The contact time of the drug with the skin
was maintained as constant (20 minutes) unless otherwise mentioned. PBS was
present in the receiver side throughout The contents of the donor and receiver
compartments were varied to assess the time required for the reversal of the
permeability of the skin samp)es in the cells. The various treatmenls were as follows:
i. The skin present in the delivery eell was putsed in the regular fashion. The drug
solution was present in the donorside and 10 pulses of20 ms each at a voltage of400
V were applied. After pUlsing, the solution was left in contact with the skin for further
10 minutes for a total contact time of 20 minutes. The cells were then emptied.
dismanUed and the amount of TRZ in the skin was detennined using HPLC. The
amount of drug recovered from this treatment is a measure of the permeation-
enhancement caused by electroporation when compared to the control samples.
ii. TRZ solution was present in the donor chamber. Eleclroporative pUlsing was as in
iii. After 10 minutes of pUlsing, the TRZ solution present in the donor side was
removed and the charnberwas washed 3 times with PBS solution. The donorchamber
was refilled with PBS, left undisturbed for another 10 minutes and then processed as
in treatment~. The amount of drug delive..ed is that delivered during the pulsing
period alone.
ii. PBS was present in the donor side. EIectroporative pulsing was as in '1.
ImmediateJy after the 10 minutes of pulsing trne buffer present in the donor side was
replaced with the TRZ donor solution. The cliffusion cell was left undisturbed for a
further 20 minutes and then processed as in treatment~. This experiment determines
the chenge in permeability of the skin immediately.after pulsing.
iv. CeUs were treated in a manner sirniar to tIllatrnent'in except tha~ the PBS was
replaced with the TRZ donor solution 5 mln...tes after the pulsing was over. The-
diffusion eel was left undisturbed for a further 20 minutes post pulsing and then
processed as in beatment lJi. This experimel'lt determines the residual change in
permeability of the skin samples 5 minutes aftar pulsing.
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v. Diffusion cells were treated in a manner similar to treat1l"lentliii except that the PBS
was rep~ with the TRZ donor solution 1 hour after the pUlsing was over. The
diffusion cell was left undisturbed for a further 20 minutes and then processed as in
treatment.. This experiment determines the residual change in permeability of the
skin samples 1 hour after pulsing.
5.1Od Studies on U__ vs. U_ relationship
Isolated skin was sandwiched in the diffusion cell (figure 3) between the donor
and receiver chambers. The stratum corneum side of the skin faced the donor side of
the diffusion chamber. The donor and the receiver sides of the cell were filled with
PBS. f:)(ponentially decaying electroporation pulses were delivered using an
electropoc'ation unit with AglAQCI electrodes. Two sets ofelectrodes were introduced
into the cell. For the outer pulsing electrodes. the anode was placed in the donor
compartment and cathode in the receiver compartment On the other hand. an inner
set of agar~KCI gef electrodes was connected to a storage oscilloscope using 10X
probes. The lower end of the agar-KCJ electrodes were in touch with the skin surface
in the diffusion cell to study the voltage drop occurring across the skin surface (U->.
As the poises were passed using the outer set of pulsing electrodes. the inner set of
e~es displayed U., as an exponentially decaying curve on the screen of the
storage osc:iUoscope. The values of U.. tor varying values ofU_and pulse length
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were determined. There were 3 holes made on each side of the chamber for the
plac:ement of the pulsing electrodes at a distance of 5. 10 and 15 mm from the skin
surface. The influence of varying the distance between the pulsing electrodes on the
values '* U.... for a given U_ value was studied. Additionally, the inftuence of
varying the area of the pulsing electrodes. white they were placed 5 mm away from the
skin. on the values of U..... was studied. The values of U..... for a small electrode (area
z 0.56 crn2) were compared with that of a large electrode (area=2.74 cm~.
5.1 De DetenninaOOn of current passing through skin dunng delivery of the
_6onp<J1se
The amount of current passing through the skin during pUlsing was assessed
by measuring the voltage drop occurring across a resistance placed in series with the
delivery electrodes (see figure 4) and was recorded in a storage oscilloscope
(Tektron~·5111.OR. USA). The value of the resistance was varied between 0.1 to
50 depending on the eJectrode area and theU_used for pUlsing. This was done
toovercome the limitation ofstorage osc::iftoscope. Foran electrode. atany given value
of U_. the oscilloscope would sometimes either fail to bigger or overshoot when
a certain amount of resistance was attached in series. Hence. the experiment had to
be repeated with a new skin sample. with a new value of resistance attached in series
with the _tion cell. The amount of current pas$ing through the skin during
pulsing was calculated using Ohm's law (FP EA, where I is the current in ampel8S, E
is the voltage drop across skin (U.... in volts), and R is the resistance in~. This
experiment was performed with both small and large electrodes using a single pulse
ranging between 2-5 ms, at U_ 100, 200, 300, 400, and 500 V. For each
determination a fresh piece of skin was used.
5.1Of Stucnes of them~ and microscopic changes in the skin due to pulsing
After detennining the optimal pUlsing conditions from the drug delivery studies
done eartier, studies were conducted on the changes in the skin due to pulsing. In
separate experments, 20 pulses of 500 V each and at varying pulse lengths (20, 30,
.0, and 60 ms) were passed to the skin samples. Similarly, the influence of using
smaU and large electrodes on the changes in the skin was studied after applying 20
pulses of 60 ms each at 500 V. Duplicate samples were taken in each case. The pH
of the donor and receiver solutions were recorded before and after pulsing using non-
bleeding co50rpHasr- (E. Merck Science, NJ, USA) pH indicator strips. Immediately
after~tion, the skin samples were fixed in glutaraktehyde fixative (D.1 M
cacodylate buffer, pH 7.2). Photographs of these post-pulsing skin surfaces (stratum
comeum and dermal side) were taken to record any superficial effects of pulsing like
bums etc. For microscopy, 0.~1.0 IJm sections of skin were cut on a Cambridge
Huxley Uttramk:rotom. The samples were stained for 2 minutes at 7(YC in 1% toluidine
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I
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Oonar solution Receptor sotution
(PBS) (PBS)
Figure 4: Experfmentlll ••t-up used for the detennlnation of the cUl'Nnt
paaaing through akin dUri~ de1ivItt'Y of tNt elec1roporation pu....
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blue in 1% sodium borate. The slides were viewed under a Phase contrast microscope
(Z8iss-IM-35). The samples were sub;ect to a 400-times magnification. Photographs
of the slides were taken on a 35 mmPe~camera using a T·Maxe (Kodak, CA, USA)
blw 400 ASA film.
5.11 Data Analysis
The experiments were performed at least five times (unless specified otherwise)
and the means:t. $.E. are reported. All the statistical analysis was performed using the
$ig~statistical &OftwIlte (Jandel Scientific. CA.. USA). Skin samples are known
to exhibit a wide variation making it difficult 10 assume a normal distribution. So non-
parametric analysis of the variance was perfonned.
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VI. RESULTS AND DISCUSSION
6.1 The choice of a skin model for transdermal drug delivery studies
The characteristics of skin are different in different mammals. These include
differences in horny layer thickness, sweat gland, and hair folJicle densities. The
sweating ability as well as the capillary blood supply vary between humans and cOmmon
laboratory animals. These factors can affect resistance, route and amount of
percutaneous absorption betNeen different species. In view ofsuch differences human
akin would be most desff'able for in-vitro studies. However, it is interesting to note that
the human skin viability, as detennined by anaerobic metabolism where glucose is
converted to l8ctose, is maximal for the first 18 hoUTS after death of donors (Wester et
at 1998). When property preserved. human skin samples retain their integrity for a
maximum of 8 days. Heat-treatedfseparated epidermis and dermis lose viability. Fresh
hu.man skin samples are not easy to acquire and the availability may vary depending
upon a number of factors such as population, demography etc. On the other hand,
animals can be easily acqUired and employed for ~thvoIin-vitrotransdennal delivery
studies. Porcine skin flaps from the caudal abdominal, inguinal. and ear flaps are
recommended models for studying percutaneous absorption (Carver et at. 1989, de
Lange et aI. 1994. and Reifenrath 19&4). Pig skin is known to slighUy overestimate
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lipophilic compound absorption and slightly underestimate hydrophilic compound
absorption (Schaefer et al. 1996). The total amount of drug delivered tends to give a
dose estimate and hence pig skin is accepted as a good substitute for human skin
samples. Mouse skin has a considerably higher percutaneous absollPtion rate and
hence, is not recommended fortransdermalstudies (Schaeferetal. 1996). Forstudying
drug absorption. an alternate approach is to use reconstituted skin in which the
keratinocytes are seeded on dermal substrate (Bell et al. 1991)Jde-epidennized dermis
(RheinwaJd 1989. and Regnieretal. 1990) andgrown in standard tissue cuJture medium.
It is also posaibIe to graft human skin onto nude rat $kin naps with he associated
microvasculature to study the percutaneous absorption in in-vMo conditions
(Wo;ciec:howski et aJ. 1987). Atthough the last two techniques are very attractive, they
arealso expensive, timeconsuming, tedious, and hence are not followed vary commonly
for percutaneous absorption studies. If human or pig skins are not easily available, the
other type of animal skin recommended and very commonly used is rat skin (Bronaugh
at at 1982). Hairtesslfuzzy rat skin has been used in our lransdermal deli1Yery studies.
Normal (hairy) rat skin needs to be shaved for such studies. This can damage the
stratum corneum making the results ambiguous. In any case, after optimizing the
eJectroporative transdennal drug delivery conditions in animal models, delivery can be
tested on viable human sUI samples.
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6.2 Electrical measurements in the skin
6.2.1 Studies on the 'relationship between u:-",. vs u_
The values of U_ achieved for the various applied values of U...- using the
dual electrode system are given in table 2 and figure 5. It was observed that all the U.....
values achieved from the first pulses were always higher than those obtained from
subsequent pulses applied to the same skin sample, even if the subsequent pulses
were applied 8 hours later. After 3-4 pulses the U_more or less stabilized at a value
lower then the initial values. The electroporator, Gene Pulse'-is designed to display
the total resistance that Includes its internal resistance and the test sample's resistance
(designated as the 'base value' prior to pulsing). This displayed resistance also drops
after the very first applied pulse and does not rise back to the base values. Since the
machine's internal resistance remains constant, the reduction in the displayed
resistance could be attributed to changes occurring in the skin. Hence, for aU the
U_vs U..... relationship experiments a skin sample was used only once to
determine the changes occurring with the first pUlse. For replicate determinations a
fresh skin sample was used.
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Table 2: The relatfon.hlp between U_and U....." for a amall electrode
u_ U_
M Mean:t:SEM
100 32.4±1.7
200 43.6 ± 2.9
300 65.8:t: 0.8
.00 83.6 ± 2.5
500 88.3 ±2.3
600 254 :t:4.2
Table 3: The amount of current paaing through the akin during pUlaln" wtth
.....--
u_ U_ Current puaing
(V) (V) through the akin
(amperes)
100 32.• 0.4 ± 0.04
200 .3.6 1.0±0.01 3
300 65.8 1.8±O.1 3
-
83.6 2.5 ±O.1 3
500 88.3 3.1 :t:O.1 3
s.
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The observations of a drop in the value of the U_ and the e6ectr0porator's indicated
circuit resistance after the initial pulsing point towards the possibility of irreversible
changes being caused by the electroporation pulses. It is envisaged that this situation
'WOuld be different in an in-vjvo setup where the skin is essentially viable. Nannal skin
undergoes continuous repair and repJacement process in response to damage and the
natural exfoliation processes. With the decrease in the resistance. and the decrease in
the observed voltage drop across the skin, an increase in the permeability of the skin is
indicated.
As the voltage drop apprl8d across the delivery electrodes was increased the
voftage drop occurring across the skin sample also increased. As Fig 5 shows U....
inaeased roughly linearly with U_. being one third to one fifth of the latter up to 500
V. A large rise in U_ occurred forU_of 600 V while measurements atu_""
700 V was not possible. Due to this reason we restrided our transdermal worit to
voltages of500 V and below. Thus. these results show that the actual volt8ge to which
the skin is exposed at the time ofpulsing is much &ower than the applied vottage and in
addition pUlsing etreds the resistance of the skin. It should be noted here that the
values of U_ quoted are the maximum values observed at the beginning of the
exponential de<:ay otU__. Itwas observed that varying the pulse length did notat'fect
the U.... vaiJes for a given U_ (observations were noted but the data is not shown
in any tabutar form).
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6.2.2 The amount ofcurrent passing through the skin during pulsing
The values of the current passing through the skin at various applied values of
the U_are given in table 3 and figure 6. The values of current are those obtained
with the small electrode. 'The values for current obtained with the larger ek!ctrode are
mentioned elsewhere in this thesis (please see table 14 on page 84). The amount of
ament passing through skin increased lineatty with an increase in the value ofU_
6.3 HPLC analysis
TRZ was quantified using a method already established in our laboratory (Singh
et at 1995). A typicaJ c::tvomatogram from the analysis is shown in figure 1. The first
peak represents the amount of TRZ and the second peak represents the amount of
prazosin (PRZ) the internal standard, in the chromatogram of the injected sample.
Calibration curves were produced on each day of analysis using stock solutions
with different concentrations of TRZ. These calibration curves resulted in statistically
well correlated strllight 6nes. The mean calibration aJNe is shown in figure 8. The
regression equation for the mean curve was:
Peak height ratio = 11.06 (TRZ concentration) - 0.02
(where R2 Z().99. n:8 3, Interday Coel'fic:ient of Variation (CV). 5.3O%.and linear range
.0.76 -7.56IJ9fmL)
57
...lOG......
~M
...,..
·+--~--~-~~-~--,..----l
•
58
4.2. 6.7
Time (minutes)
Flg"",7: A typical chromatognm _nod from tho~of_In.
59
0•• ,------------------,
o.s
~EO,.
~
~ 0,3
CO
8. 0.2
if
0:1
.~
0.0
CV 5.30% (n=3)
~ concentration (mglmL)
FIg.....: ca...-n eurw for TRZ u.Jya1s Ilv HPLC
60
I
I
I
I
I
I
I
I
I
I
I
6.4 Eight hour transport studies
Figure 9 shows the profile obtained for TRZ delivery into the receiver using 20
pulses at U_ ;: 400 V. 't = 5 ms. There was a phase lag of one hour before a
measurable quantity ofTRZ was detected in the receiver.
The cumulative amount ofTRZdelMtred in the receiver in 8 hours using 5 pulses
of5 ms each atdifferentU...- voltages are given in figure 10 and table 4. Therewas
nostiltisticaJtysignific:antdifference(p>O.05)betweentheamountofTRZdefiveredwflh
control .nd with 200 V. 'JVith 300 V there was a marginal increase in the TRZ delivered.
With U of 400 and SOO V there was • significant increase in the amount of TRZ
delivery (p < 0.05) compared to control. However, at 400 and 500 V there was no
significant (p > 0.05) difference. Furtherstudyto determine the influence ofpulse length
and number of pulses, was dc;»ne at U_ 500 V. The results are shown in table 5.
Increasing the number of pulses from 5 to 20 atU_500 V ('t .. 5 rna) increased the
cumulative TRZ delivery by four times. Doubling the pulse length from 5 ms to 10 ms
<at 500 V. 20 pulses) had much greater impact and the TRZ delivery increased by about
five times more.
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Table.: Cumu"ttv. amount of TRZ delivered in 8 hou... in the receiv.r using 5
pul... of 5 ma .ach at different U.--. Yoltages
u_ Amount of TRZ deliv.Net n
(I/) in receiver
Mean (l.Ig) : SE
Control (0) 0.1 :0.02 5
200 0.1: 0.02 5
300 0.2*0.1 5
400 0.6:0.2 5
500 0.9* 0.3 5
Table 5: Cumu"ttv. amount of TRZ delivered in 8 hou... In the receiver using
U....... 500 V at different pulefng condJtiOM
Treatment Amount of TRZ deliv.red n
In recefver
Mean (1'9). SE
Control (0 pu....) 0.04 :0.02 •
5pu!sesX5ms 0.7 t 0.02 •
20 pulses X 5 ms 3.3t 1.3 •
20 pulses X 10 ms 14.6 t3 •
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Flgurw 10: Errec:t ofU_. on TRZ delivery
(8 hours study)
In all the above experimental results, it was seen that TRZ transport continued for a long
time (at least 8 hours) after the delivery of the electroporation pUlses. This could be
attributed to a 'depot-etJect'. Apparentty, TRZ depot forms in the skin as soon as the
electroporation pulse is delivered and then the drug diffuses out slowly over a long
period of time. C3fculation of the cumulative TRZ delivered in the 8-hour study (Sge
table 4) exhibited large standard deviations. It is envisaged that these large dev~ations
in the results were introduced due to two problems in the experimental design. Firstly.
although freshly excised skin was used in our work, its viability deteriorated over the
period of 8 hours. Secondly, the differences amongst the skin samples, especially
abdominal and back skin introduced addttional variations in the results. Toelueidate this
further skin samples from different regions of the same animal were subjected to TRZ
delivery using 20 pulses of 10 ms each at 500 V. From the results (table 6) it appeared
that the abdominal skin was five times more permeable than the back skin. To furUler
investigate the differences in skin type, the amount of TRZ delivered in the skin was
quantified. In this study TRZ delivery in the skin immediately after the de{ivery of 20
pulses, 10 ms at 500 V was quantified. Interestingly. there was no significant difference
(p > 0.05) in the amount of TRZ delivered in the skin (table 7). From this it may be
inferred that the total amount of TRZ delivered in the skin during pulsing is the same
and, in this respect there is no difference between the abdominal and back skin. The
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Table I: Influenee of skin type on the cumu18tive amount of TRZ delivered in 8
hours in recefy.,. after 20 puts.. T -10 nq; atU_ = 500 V.
Sldn type
abdominalsJdn
back_
c:cntroI.
Amount ofTRZ delivered
in receiver
Mean(~)±SE
24.3 ± 5.3
4.9± 1.1
0.05 *0.02
Table 7: In"lIenee of akin type on the amount of TRZ deUveNd in skJn after 20
puts-. T -10 mao u_- SOO V.
Sldn Type
abdominal skin
back skin
control
Amount of TRZ delivered
in skin
Mean (JJg)±SE
31.9:t3.6
32.9 ±2.9
4.03 ± 0.34
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difference between abdominal and back skins seen in the s.hour transport study (tabhl
6) is due to anatomical differences in the two skin types mentioned. Rat abdominal and
back skins have been seen to vary in stratum corneum thickness as well as the
percutaneous absorption rate of compounds (Btonaugh et al. 1983). Hence. the
diffusion ofTRZ through different thicknesses of the skin varied. Based on the above
findings, it was decided to conduct aU transdermal electroporation experiments by
quantifying TRZ in the skin and the receiver after putsing. This also allowed us to use
the entire sldn of the hair1ess rat without differentiating into abdominal and back skins.
6.5 Effect of eJectroporation parameters on the delivery of TRZ into skin
Electroporative transdermal delivery is primarily governed by the voltage, pulse
length, and number of pulses used (Wang et 81. 1991). Although there are few papers
published in this specific area of research by different wor1(ers including us, the work is
far from complete.
The U_changed after the 1st pulse and subsequent pulses (see above). The
U_is the voltage set on theelectroporator. To maintain constant U..... would require
a sophisticated electronic set-up which has not yet been devised. Hence, in all our
discussions reference has been made only to U_.
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6.5.1 InftuenceofU_
TRZ delivered into the skin using 20 pulses of 20 ms each at different U__
values ranging between 100 and 500 V are shown in tatMe 8 and figure 11. Control
indialtes TRZ that was delivered by passive diffusion alone. Using an U--. of 200
V did not produce any significant TRZ delivery enhancement over the control. At 300
and 400 V the 1HZ delivery was seven and thirteen times higher than the control,
respectively. Although a further increase in U_ to 500 V produced fourteen times
increased delivery of TRZ compared to control, there was no statisticatly significant
difference (p> 0.05) between the deliveries achieved with 400 and 500 V. This is
visualized from figure 11, where there is a linear relationship between U...- and TRZ
delivery in the 200 to 400 V range.
Our findings are consistent with those reported by Pliquett et al. (1996). They
have reported that a minimum U_ of 75 V has to be exceeded to observe a significant
enhancement In the permeability of the epidermis. From ourexperimental resutts it was
found that for the U_200, 300, 400, and 500 V the corresponding U..... were 43.6,
68.7, 83.6, and 88.3 V respectivety. Thus for our experimental set-up it required a U_
of 68.7 V to observe a five times enhanced delivery of TRZ compared to the control.
The marginal increase in TRZ delivery from 13 to 14 times that of control, with the
increase in U_values from 400 to 500 V is consistent with the nominale~
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Table': AmountofTRZ d.UveNet in akin ~ing 20 put.ea of-or-20 rna .ach
uaing a email electrode at different U_ voltasr-.
u_ Amount of TRZ deliver.d
(V) in akin
Mean(~):t:SE
0 4:tO.5
200 2.8:t: 1.0
300 28.1:t 1.2
.00 53.5:t1.7
500 58.7:t5.6
Table 9: Amount of TRZ deliv.Net in .kln by applying 20 pul... ofU_ 500
V ualng a email electrode at dHfeNnt pulae Iengtha: (-or)
PuIH length ('t) Amount of TRZ delivered n
ms In akin
Mean (1JQ):tSE
0 4 :to.5 5
10 28:t 1.8 5
20 58.7 :t5.6 5
30 79.3:t 1.5 5
.0 151.7:t: 16.3 5
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increase in the corresponding U.... values from 83.6 V to 88.3 V. It is important to note
that increasing the U_ to 600 V caused a sudden jump in the U_to 254 V. This
was accompanied with visible damage to the skin manifested as deep bum marks.
Hence, drug delivery experiments at 600 V were not attempted. From these
observations it can be conduded that with regard to U..... values. U_ values of 300
to 500 V appear to be a useful operating range. Below 300 V there is minimal
enhancement in the permeability of skin and above SOD V it may be detrimental to the
safety of the skin.
6.5.2 Errect of pulse length
Pulse length had a profound effect in increasing the permeabYity of skin. Based
on our experimental results it is the second most important electroporative parameter.
afterU_. TRZ delivery obtained using 20 pulses at SOD V (U-> at four different
pulse lengths viz, 10.20,30, and 40 ms are shown in table 9 and figure 12. Similarto
the effect ofU_ here also there seemed to be a linear relationship between the
pulse length and TRZ delivered up to 30 ms. Use of pulse lengths of 10, 20 and 30 ms
enhanced TRZ delivery, compared to control, by 7, 14.5 and 20 times, respectively.
However. use of40 ms pulses enhanced drug delivery by about 38 times, as compared
to control. Damage to the skin seemed to appear with the use ofpulse lengths of30 and
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40 ms. To further ascertain these findings, the histological details of the pulsed skin
were studied under a light mic:toSCOpe. The details of this study are given in section
6.7.2.
6.5.3 Effect of the number of pulses
The number ofpulses is the third most important parameter, after U__ and
pulse length. From the previous experiments pulse lengths of 30 and 40 ms seemed
debimental to skin's safety but these studies had been done with the use of20 pulses.
It was not known whether the skin would be damaged with fewer pulses. Since, 20
pulses of 40 ms are known to cause a visible damage to the skin, this part of the
experiment was pursued to determine the effect of the number of pulses with 40 ms
as pulse length.
Asingle electroporation pulse with 500 V (U-> at40 ms enhanced the TRZ
delivery by 3.5 times. This seemed significant but not adequate. As the number of
pulses wet'e inaeased, the amount of TRZ delivered to the skin also increased,
although not proportionatety (tab4e 10. figure 13). Use of 5 pulses increased TRZ.
delivery, compared to the control, by 9.9 times but use of 10 pulses increased the TRZ.
delivery only 10.8 times. The Use of 20 pulses gave a very sharp 38 times increase
in TRZ. delrvery. Hence, with each appl;ed pulse, the permeability of the skin sample
keeps on increasing slightly. Upto 10 pulses, no bum marks indicative of physical
damage were visible on the skin surfaces.
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Table 10: Amount of TRZ delfv"" in akin by .pplying varillble number of
pulaea ofU-..- SOOv. 't -.-0 ma uaing a aman .lectrocle.
Number of pu'" Amount of TRZ deliverad n
Mean CIJg) ±SE
0 4±0.5 5
1 11.8±1.8 5
5 39.3 ± 1.4 5
10 43 ± 3.6 5
20 151.7 j: 16.3 5
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6.6 Electrode design
6.6.1 Effect ofdistance between delivery electrode and skin
The diffusion cell designed for the U..... studies had three bores in both donor
and receiver sides for placement of the deJivery electrodes. Due to this arrangement
the delivery electrodes could be placed at 5 mm, 10 mm, and 15 mm from the skin
surface to study the influence of distance between electroc:le and skin on the values
ofU_whichareshown in the figure 14 and table 11. Changing the distance between
the skin and the delivery~es appeared to have a trend that suggested that
$kirKie(iYefy~ distance dkS atrect the U..... values. The U.... value appeared
to decrease as the delivery electrodes were moved away from the skin surface.
However, no statisticalty significant differences were found between the values, with
these sman number of samples.
6.6.2 Effect of 'elsctrode 8188' on values ofU., and dr1Jg delivery
The effect of electrode design with particular reference of area, has not been
systematicaly studied by any of the research groups in electroporative drug delivery
research. Therefore, experiments to study the effect of electrode area on drug
delivery and safety issues were performed. To increase the electrode area, a long
piece of Ag I AgCI wire was spiralled to obtain a >fold increase in the area (2.74 cm2).
The aru ofthe small electrode which was basicalty a straight wirewas 0.56 cnr. The
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Teble 11: Ef'fKt of dietance betwMn delivery electrode end akin.
U_M U_M Skin-deliftry electrode n
Mean±SE dlsgnce(mm)
200 40:t8 15 3
200 42 ±6.6 '0 3
200 50 ± 11 5 3
300 55:!:4 15 3
300 61.3±4.3 '0 3
300 67.3 ±5 5 3
400 65%6.1 15 3
400 70:1:5 '0 3
400 71.3 :t5.2 5 3
n
lDO
-.U_-400v
00 -.-- U_-300v
~U_.200v
eo
W ~(I) 70+.~ eo'"~ 50
:>
40
30
n=3
20 1. t5
Distance between electrode and skin (mm)
Flgu.. 14: EII'ect of distance _ dellwry._ end skin
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area ofthe electrode was calculated by assuming the wire to be a cylindrical piece (2n
rl +n~,where risthe radius. 0.025 an; listhe length, 3.54cm and 17.4 cmforsmall
and large electrodes. respectively). The U..... values determined with the large
eJectrode gave a 30-40 % increase compared to the small electrode (table 12 and
figure 15). This would mean that to obtain a certain U_. with the use of a large
electrode, it would be possible to use a lower UoIoclr<IcIt. One obvious benefit would be
the need for an electroporator with smaller capacitors. With further research in
electrode design there would be a possiJility of miniaturizing the electroporation unit
to make it portabCe.
In order to determine if the Increased area electrodes (that enable the use of
lower U-> also delivered the corresponding amount of TRZ, drug delivery
experiments were perfonned using two concIitions: 5 pulses of 10 ms and 20 ms. The
U~of the small and large e4ectr0des were chosen to obtain similar U...... with the
first pulse. The U..... obtained with the small (U_ = 500 V) and large electrodes
(U-..." 316 V) were the same (88.3 V). The results are shown in the table 13 and
figure 16. There was no statistically significant alfference in the amount of TRZ
delivered with both small and large electrodes. Thus, the use of large electrodes
would allow one to use smallerU~ fordrug delivery. In ourdrug delivery studies.
all of whk:h were done using the sma" electrodes. pulsing at a high pulse length
(higher then 20 ms at 500 V) mostly led to black marks on the skin surface indicating
bums. The bum marts corresponded in shape and size to that of the electrode
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Ta"" 12: n. influence of electrode area on the valu.. of U_
corrnpondlng to the appUed U_.
u_ U_(Small electrode) U.... (Large ektctrode) Percentage
M Mean:t:SEM Mean ± SE (V) Increment
"
100 32.4:t: 1.7 48.t 1.4 48 5
200 43.6 :t:2.9 57.t2.4 31 5
300 65.75.t; 0.8 82± 1.6 25 5
400 83.6 :t:2.5 111.2:t:2.1 33 5
500 88.3:t:2.3 116.t22 31 5
600 254:t4 338.0 33 5
Table 13: The err.ct of electrode a,.. on drug delfyery
Typo of U_ Us"'" 1 Number Amount of
"
.- M M (mal ofpu.... TRZ delivered
(area) Mean (1JQ):tSE
Sman 500 86.3 10 5 6.5:tO.7 5
large 316 66.3 '0 5 6.7:t 1.2 5
Sman 500 86.3 20 5 14.7:t3.2 5
la'9" 316 86.3 20 5 13.3:t 1.6 5
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being used for electroporation. However, the large electrodes used in our studies did
not produce the bum marks unlike the small electrodes. It seemed that our large
eJectrode design could have a similar effect in current distribution as has been
mentioned by Wiley and Webster (1982) in their work on the effect ofelectrode design
~ overall and local current density as applied to electrosurgery. According to these
authors there exists a significant difference between overall and local current
densities. Overalt current density is based on the area of the electrical contact with
the skin. Local current density under an electrode is highly variabJe. with greater
current densities along its edges. It was seen earlier that patients undergoing
eIectrosurgetysuffered from bums around the perimeterof the dispefSive eJedrodes.
Circular dispersive eJectrodes which produced more uniform current distributions by
forcing a more effective utilization of the entire area were proposed. Applied to
eledroporltive transdermal delivery, we saw that the use ofa large electrode not only
delivered the same amount ofdrug at a lowervalue ofU_as compared to a small
electrode. but with the additional advantage of reduced incidence of skin bums.
6.6.3 £ffecI ofeJectrode ama on the cummtpassing through skin and overall current
density
The etreetofthe area of the electrode used for pulsing on the amount ofcurrent
passing through the skin was checked. An experiment was designed which was
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similar to the one done earfier (section 6.2.1). It was found that the currents passing
through the skin at various values ofU_were about 3 to 4 times greater for the
large electrode as the current passing for the small electrode(Table 14 and figure 17).
The area ratio was about 5 so one might expect this ratio of currents.
The plots of U.... V$ Joules per puise. with respect to skin area and electrode
area (small and large) are shown in (table 15) figures 18 and 19, respectively. Due
to technicallimbtions we could detemline the currents only at lower pulse lengths,
ranging between 2 and 5 rna. However, we believe that the basic infonnation obtained
relating energy and area of the skin and the electrode, is stilt meaningful and useful
in explaining the results obtained by us. During each current measurement the exact
pUlse length was determined and used in arriving at the energy values reported in
figure 18 and 19. The changes in the skin's stratum corneum, caused by
electroporation putses. can be expected to depend on the area of the skin exposed
to the cunent and this appeared to be the case. The slopes of the plots obtained
. using skin area to calculate the energy per unit area per pulse. shown in figure 18, are
similar. In other words, the energy delivered to the skin appears to be similar,
irrespective of the area of the electrode, and seems to primarily depend on the
vcWtage, U...... and pulse length. If this were trUe, a bum scar would have been
observed for the 60 ms e4ectroporation puises, not only for delivery using the
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Table 1.: Etrect of electrode .re. on the v.l~ of current puaing
through akin
Cu.....nt pasaing through akin
M (amperes)
Small el&ctrode Large electrode
100
200
300
.00
(area z 0.56 cml)
1.03 :1:0.01
1.82 ±0.06
2.51 ±0.09
(area = 2.74 crrr>
1.21: 0.27
3.35 ± 0.47
5.82±0.79
9.33 ± 0.79
soo
M
3.08:1:0.12 12.79±0.84
Table 15: Energy delivered to the akin
energy delivered to the akin (JouIes.puJse"~
(energy/electrode area) (energy/skin area)
Smell Large Small Large
eIoc.-
-
electrOOe e1ectJDde
(JouIes.pulse"' (Joules.pulse·' (Joules.pulse" (Joules.pulse"
O.56c::rn4) 2.7.. an~ '1.3cm~ 1.3an~
100 0.17 ± 0.02 0.08 ±0.02 0.07 ± 0.01 0.16:0.G4
200 0.41 ±O.O 0.17 :0.02 0.18±0.0 0.36 ± 0.05
300 1.09 ± 0.04 0.41: 0.06 0.47 ± 0.02 0.86 ±-0.12
.00 1.91 ± 0.07 0.81 ± 0.07 0.82: 0.03 1.71 :0.14
500 2.37 ±0.09 0.95 :0.06 1.02 ± 0.0. 2.01 ± 0.13
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smaU.-area electrodes but a150 for the large electrodes (see section 6.7.2). When
energy per unit area per pulse was calculated with respect to electrode area and
plotted against U.,. very different profiles were obtained (figure 19). The large
electrode delivered 2 - 2.7 times less energy to the skin when compared to the smalJ..
area electrode.
6.7 Safety of electroporation
The safety of transdermal electroporatjon is an important issue. Just as any
otherpenneation-enhancementtechnique eJectroporation would be useful only when
the optimized condition of use is both efficient for drug delivery, as wen as safe to the
sldn. Although the barrier property of the skin woukf be broken down to achieve
permeation-enhancement with electroporatjon, the process shoukf be reversible and
there shoukf be no permanent and/or long term damage caused to the skin. A
complete study of safety issues will invotve in-vitro as well as in-vivo work. In this
project~vitroexperiments were doneto get initial infonnation about the safety of this
technique. The two in-vitro studies carried out were 'reversal of permeability' and
'histological examination of sldn', which are descti:Ied bekJw.
6.7.1 Reversal of permeability enhancement
This experiment was specificaty designed to gain an insight on how
electroporative permeation-enhancement takes place in the skin and how kJng do the
effects lasts. In other words. this studywoukf fumish information on the safety of the
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technique and provide some tips on the mecflanism of the electroporative
enhancement The results are presented in the form of a histogram in figure 20. The
histogram bars labeled 2 and 3, standout with TRZ quantities 27.7 ~g and 20.35 .,g,
respectively. They represent electroporation pulse delivery with the TRZ solution in
the donor chamber. In histogram 2, the TRZ solutiom had been left in contad with the
skin durtng and after the pulse, while in the histogram 3, the TRZ solution was
replaced by PBS immediately after delivery of the pulse. Although with the small
number of samples (n '" 3), there was no statistical difference (p>O.05) between the
two delivertes (histogram 2 and 3), the mean TRZ delivered in the case where the
solution was left in contact with the skin during and after the pulse, was 25% larger.
The other histogram bars viz, 4, 5 and 6 (which were respedivefy, for TRZ added
immediately after the pulse, five minutes after the pul$8 and one hour after the pulse)
were much smaller and statisticalry not different (P:>(l.05) from the controls. This
dearty demonstrated that the permeation-enhanc:ement in the skin occurred primarity
durtng the electToporation pulses. tt is speculated th~ the permeation.-enhancement
is due to creation of aqueous pores in the stratum CoOmeum (Pliquett et at 1996a).
Since adding the TRZsolution immediately after the pulse did not show any significant
increase in delivery compared to the contrd, it appealr$ that the pores created close
very quietly. This is also in agreement with the reports ofPliquett et at tt should be
noted that In this experiment the electroporation conditions (20 pulses, 't '" 10 rns,
U_ = 400V) was carefulry chosen to ensure that the penneation-enhancement
was achieved with a minimal Hctric force. This was done to ensure that the
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reversibility of permeation was influenced primarily by time and there was IittSe effect
due to excessive electrical force that could cause skin damage. Itwas speculated that
using a higherU_ (e.g.. 600 V orlarger) and/or pulse length (e.g., 30 ms or larger)
would make the skin behave dit'ferentty. Depending on the severity of the
eleetroporation conditions the permeation-enhancement could be much more
prolonged but it may not revert to the base level at aU. This information could hence
be used as an indicator of safety for the elecb'oporation technique.
6.7.2 Macroscopic and mk:rosoopic changes in skin due to electroporation pulse
Attempts were made to c:omtiate the inferences made until now regarding the
upper limits of U__ and pulse~. with any macroscopic and/or microscopic
changes in the skin. Since pulses with U_ of 600 V produced a very steep
increase in U.... (figure 5) causing visua!y detectable damage to the skin, there didn't
seem any need to prove it further. Twenty pulses with U_ of 500 V having
different pulse lengths were chosen for studying the histotoglca!l changes in the skin.
In each case the pH in the donor and receiver compartments before and after
electroporation were also detennined. which are given in table 16. With the control
sample the pH of the donor and receiver compartments remained unchanged at pH
6.4. With the 20 ms pUlse length experiment. the donor pH remained unchanged
while that in receiver went up from 6.4 to 8.0. As the pulse length was increased to
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Table 16: Influencing of .5ec::tro~tfyepulsing on the pH in the receiver and
donor chambers
Trutment n Initial Final Initial Final
donor donor receiver NCeiv.rV_go , ••f EIK_
M (m_)
...- ....
pH pH pH pH
a a a small 2 6.4 6.' 6.' 6.'
500 20 20 small 2 6.' 6.' 6.' S
500 30 :io small 2 6.' 6.' 6.' 11
500 ao 20 small 3 6.' 6.' 6.' 12
500 80 20 small 5 6.' 6.' 6.' 12
500 60 20 large 3 6.' 6.' 6.' 12
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30 ms the pH in the receiver increased to 11. At pulse Jengths above 30 ms the pH
of the receiver rose to 12. Such a large increase in the pH can result in
irritationfchemical damage to the skin or may even result in the degradation of the
sensitive drugs. The change in pH was accompanied by a significant amount of
foaming in the receiver chamber (cathode), which was absent in the donor chamber
(anode). VJhen a high currenttlows at the reactive electrode. AglAgCI in the presence
of C( ions, the Ag would be converted to AgCI and no foaming should be expected.
However, at the cathode, the AgCI would first be reduced to metallic Ag. Upon
completion ofthis process (oreven in parallel with it) the extra current would generate
hydrogen gas from water. This may also be represented using the following
equations:
Donor (anode) side
Ag (s) + cf(trom PBS) ->Agel (5) + e-
ReceNer (cathode) side
2H20 (I) + 2e-->H2 (g)+20H-
In the receiver chamber the hydrogen gas formed caused the foam and the
hydroxyl ions formed raised the pH. Increase in the pH to 11 or 12 with pulse lengths
30 ms and above is indicative ofgeneration of large currents that could cause damage
to the skin. The reactive AglAgCI eleetrodes are nonnalty not expected to cause the
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eiec:tro/ysis of water, which causes such drutic pH changes (Phipps et a!. 1989, and
Burnette et aI. 1987). The htgh currents used here, even transitorily, are larger than
those encountered in usual electrochemical experience and hence, the above
scenario is quite probable.
In order to detennine the effect ofalkaline pH, the skin was exposed to dilute
sodium hydroxide (pH 12) for20 minutes. Subsequentexamination ofthe skin did not
show any damage similar to that seen with the passage of electroporation pulses of
30 and 40 ms. This indicated that the visible skin damage mentioned eariiefprobabfy
did not arise solely from contact with alkaline sQlution.
Two sets of skin samples were chosen for observing changes due to
electroporation pulses atdifferentsettings. The first setwas photographed to observe
any gross changes visible to naked eye. The other set of skin samples was fixed in
glutaraldehyde fixative and their cross sections were prepared for observation under
a phase contrast microscope. The simple photograph and the Ught microscopic
photographs of the control skin are shown in Figures 21 and 27 respectively. Please
note that the photographs show onty the area of the skin which was exposed to the
drug solution. In all the test conditions theu_was kept constant at 500 V and the
number of pulses were kept at 20. The variables tested were putse length and area
of the electrode.
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Vl$ual examination of the skin samples indicated that there was no obvious
damage at the stratum corneum or dermal side with use of 20 ms and 30 rns pulses
(Figures 22 and 23). As the purse length was increased to 40 ms, red patches were
seen on the dennal side and a few dark patches were seen on the stratum corneum
side (Figure 24). \f\Mh the use of60 ms pulse a dark mark was seen on the stratum
corneum side (FlQure 25) which looked like a bum mark. The dennal side of the skin
also bore red and black patches. In all the above tests small eJectrodes were used.
However, it was very interesting to find that when the skin was subjected to
electroporation pulses of 60 ms, using the large electrode (with the k)op design and
U..... the same as for small electrode), the visually apparentdamage was much lesser
(FlQure 26) compared to the skin subjected to 60 ms pulses with the small electrode.
VYhen two 1i~lectrodes (small electrodes) placed parallel to one another in an
electrolyte solution are involved, current flows principally between the two wires and
widens out like magnetic iron filings pattern between two point magnets (Kasper
1940). In our case, because the skin pmced between the eh!ctrodes was not
electrically conducting, the current flow was not uniform over the skin surface when
the small·area electrodes were used, and a bum occurred at 60 ms pulse length. The
burn mark corresponded to the general shape (straight piece ofw;re) and orientation
of the electrode, which was probably the main path followed by the current With the
large electrode the current seemed to have been delivered more unifonnly, thereby
preventing a bum.
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Figure 21a: Stratum corneum side of a control skin sample
Figure 21 b: Dennal side of e control skin semple.
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Figure 228: Stratum corneum side of a sldn sample sUbjected to 20 puis..
of 500 V and 20 me each using a small electrode.
Agure 22b: Dermal side of a sldn sample subjected to 20 puis.. of 500 V
and 20 me each using a small electrode.
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Figure 23a: Stratum corneum side of a skin sample subjected to 20 pulses
of 500 V and 30 ms each using a small electrode.
Figure 23b: Dermal side of a skin sample subjected to 20 pulses of 500 V
and 30 ms each using a small electrode.
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Figure 248: Stratum corneum side of a skin sample subjected to 20 pulses
of 500 V and 40 ms each using a small electrode.
Figure 24b: Dennal side of a skin sample subjected to 20 pulses of 500 V
and 40 ms each using a small electrode.
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Figure 25a: Stratum corneum side of a skin sample subjected to 20 pulses
of 500 V and 60 ms each using a small electrode.
Figure 25b: Danna! side of a skin sample subjected to 20 puis.. of 500 V
and 60 ms each using a small electrode.
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Figure 2ea: Stratum corneum side of a skin sample sUbjected to 20 pulses
of 500 V and 60 ms each using a large electrode.
Figure 2eb: Dennal side of a skin sample subjected to 20 pulses of 500 V
and 60 ms each using a large electrode.
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Examination ofthe cross sectional right microscope photographs corroborated
the above findings. In the control skin sample the different layers ofskin were clearty
demarcated (Figure 27). For the skin samples sUbjected to eJectroporative pulsing,
as the pulse lengths were increased from 20 to 60 ms, there was progressively
increased damage to the skin. At one end of the spectrum with the pulse length of
20 ms, the different layers ofepidennis and dermiswere clearty visble, whereas at the
other extreme with the pulse length of 60 ms, the different layers ofdermis had gelled
together (Figure 28 to 31). As the pulse length was increased gradually from 20 to 60
ms, the damage to the skin also increased progressivety. The skinsam~ subjected
to eIectroporation pulse with the increased area electrode did show some damage
(FJgure 32) but itwas much lesser than thatcaused with the small etectrode with same
eJectroporation conditions.
Based on the above findings it may be reasonable to condude that using 20
pulses with an U of SOO V, and pulse length of 20 ms is relatively safe. The
damage caused to the skin seems to be minimal and the skin reverts back from the
enhanced penneation mode to the base level within one minute. Use of a loop
electrode with larger area and hence. smaller U_, also seems to be a more
efficient way to use the technique.
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FIgure 27: Microscopic cro....ectlon of a control skin sample.
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Figure 28: Mlcro.coplc cro....ection of a .kln .ample .ubjected to 20
pul.es of 500 V and 20 rna using a small electrode.
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Figure 29: Microscopic cross..ectlon of a skin sample subjected to 20
puls88 of 500 V and 30 me using a small electrode.
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Figure 30: Microscopic cross-sectlon of a skin sample sUbjected to 20
pulses of 500 V and 40 ms using a small electrode.
\07
FlgUnl 31: Mlcro.coplc cro..·.ection of a .kln .ample .ubjected to 20
pul.e. of 500 Vand 60 ms u.lng a .mell electrode.
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FlgUnl 32: Microscopic cross...ectlon of s skin sample sUbjected to 20
puis.. of 500 V and 60 ms using a large electrode.
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VU. CONCLUSIONS'
1. EJectroporative pulsing causes a dramatic increase in the delivery ofterazosin into
skin. For example, electroporative delivery with 20 pulses at U-. of 500 V. pulse
length of 20 ms resulted in 15 times increased delivery ofTRZ into skin, as compared
to passive diffusion.
2. Electroporative permeation-enhancement was transient and reversible provided
the conditions of pulsing were controlled.
3. EIectroporative transdermal delivery was rMIrkedly influenced by:
i. U.., {U-->: N the values of U_ were increased. above a threshold (or
minimum) value. there was almost a linear increase in the delivery ofterazosin into the
skin.
ii. Pulse length: Pulse length had a profound inftuence on the defrvery of
terazosin into the skin. The increase in the amount of Terazosin delivered into skin.
corresponding to the pulse length, was almost linear.
iii. Number of pulses: Delivery of terazosin occurred with each pulse. Hence,
as the number ofpulses was increased. the amount delivered also increased, almost
Iinearty.
iv. Electrode design: Therewas a signifieanl change in the current density, and
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voltage drop across the skin associated with the electrode design. With five times
increase in the electrode araa U__ could be reduced by 40% to achieve a u_
comparable to that obtained with an electrode of a smaller area.
It can be reasonably concluded from the results that pulsing with a U_of
500 V and a pulse length of 3{) ms fanns a borderline below which eleetroporation is
relatively safe.
4. U.....: The U.... values were about one third to one fifth thatofthe U_depending
on the vottage used. TIle area of the pulsing electrode also influenced the U....
values. For instance. an increase in the electrode size by about 5 times increased the
value of U_ by 30-40%.
5. The large electrode delivered 2 - 2.7 times less energy to the skin when compared
to the smarr eJectrode. An increase in the area of the delivery electrode is speculated
to result in a more even distribution of the current resutting in less damages to the
skin.
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VIII. Pro8pecta and Fututa Directiona:
This project addressed issues related to the optimization and the safety of
eIectroporation as applied to transdennal drug delivefy. Studies related to thedelivery
of drug into the skin instead of delivery across the skin (Il"Ito the receiver) were found
to be more satisfactory for the in-vitro studies. The pulsing conditions were found to
strongly in1luence the transdermal delivery of the model drug (TRZ). This shOW$. that
it would be ultimately possibJe to predict and control. to quite an extent, the
transdermal delivery using eJectroporation. The inftuence of the drug concentration
on the donor side is another factor that may affect drug delivery and it should be
studied. The optimisation and safety issues addressed in this WOf1( form a ground
WOI1c. for trying out transdermal electroporatiYe delivefy in-v;vo under the optimized
conditions. Damage to the skin on the macroscopic and microscopic levers were
detected after Mectroporative pulsing beyond certain conditions. rt would be
worthwhile at this stage to perceive the changes occurring in the skin at the molecular
level after pulsing at different conditions using techniques such as the NMR (Kitson
et al. 1994. Bowstraetal. 1997 and Banyet al. 1995), DSC (Lee etal. 1998). Small
Angle X-Ray Diffraction. \/Vide Angle X-Ray Diffraction (Jadoul et at 1997). and ATR-
FTIR (Harrison et ar. 1996) etc. The permeability barrier of the skin has been
attributed to complex crystalline structures in the stratum corneum with lipid portion
like ceramides and choiesteroI. Work needs to be done for studying the possible
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changes in the type of crystalline structures present in the stratum corneum after
eAectToporatrve pulsing. Keeping in view the changes in the permeability of the skin
after pulsing, transepidermaJ Water loss (TEVVL) can be expected to change after
eJectroporatiYe puising at different conditions and needs to be studied in detail in in-
vivo studies. Finally, electrochemotherapy using bleomycin has been found to be very
effective and useful in recent clinical trials in treating skin cancer (Glass et aL 1997).
EJectroporation has been speculated to increase the effectiveness of the anticancer
drug molecules. The mechanism of the increased etJectiveness is believed to be the
increased permeability of the drug irlside the already highly permeabifity cancer cells.
As • result, bIeomyc:in which • not conventionaDy used in skin cancer treatments was
very effective. In the same context, it might be interesting to do similar
electrochemotherapy studies using naturally occurring anti-cancer moieties such as
vincristine (Knyihar-CsiUik E et al. 1982) for skin cancers.
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